UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
_________________
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER
THE
SECURITIES EXCHANGE ACT OF 1934
Date:
March 6, 2023
UBS
Group AG
Commission
File Number: 1-36764
UBS
AG
Commission
File Number: 1-15060
(Registrants'
Name)
Bahnhofstrasse
45, Zurich, Switzerland and
Aeschenvorstadt 1, Basel, Switzerland
(Address
of principal executive offices)
Indicate
by check mark whether the registrants file or will file annual reports under
cover of Form 20‑F or Form 40-F.
This
Form 6-K consists of the UBS AG audited standalone financial statements for the
year ended 31 December 2022, as well as the consent of Ernst & Young Ltd.
with respect thereto, which appear immediately following this page.
UBS AG
Standalone financial statements and regulatory
Information for the year ended 31 December 2022
UBS
AG standalone financial statements
(audited)
Income statement
|
|
|
|
|
|
|
|
|
|
|
|
|
USD m
|
|
CHF m
|
|
|
|
|
For the year ended
|
|
For the year ended
|
|
|
Note
|
|
31.12.22
|
31.12.21
|
|
31.12.22
|
31.12.21
|
Interest and
discount income1
|
|
|
|
7,133
|
4,091
|
|
6,821
|
3,745
|
Interest and
dividend income from trading portfolio1
|
|
|
|
2,199
|
2,572
|
|
2,097
|
2,360
|
Interest and
dividend income from financial investments
|
|
|
|
359
|
115
|
|
344
|
105
|
Interest expense2
|
|
|
|
(9,197)
|
(5,128)
|
|
(8,799)
|
(4,704)
|
Gross interest
income
|
|
|
|
495
|
1,649
|
|
463
|
1,506
|
Credit loss
(expense) / release
|
|
13
|
|
18
|
78
|
|
17
|
72
|
Net interest
income
|
|
|
|
513
|
1,727
|
|
480
|
1,578
|
Fee and commission
income from securities and investment business and other fee and commission
income
|
|
|
|
2,756
|
3,703
|
|
2,618
|
3,390
|
Credit-related
fees and commissions
|
|
|
|
99
|
109
|
|
95
|
100
|
Fee and commission
expense
|
|
|
|
(684)
|
(810)
|
|
(651)
|
(741)
|
Net fee and
commission income
|
|
|
|
2,171
|
3,002
|
|
2,062
|
2,749
|
Net trading income
|
|
3
|
|
5,796
|
3,623
|
|
5,512
|
3,301
|
Net income from
disposal of financial investments
|
|
|
|
(110)
|
56
|
|
(106)
|
52
|
Dividend income
from investments in subsidiaries and other participations
|
|
4
|
|
6,465
|
6,401
|
|
6,183
|
5,882
|
Income from real
estate holdings
|
|
|
|
394
|
480
|
|
375
|
439
|
Sundry ordinary
income
|
|
5
|
|
1,467
|
1,342
|
|
1,397
|
1,229
|
Sundry ordinary
expenses
|
|
5
|
|
(937)
|
(338)
|
|
(888)
|
(308)
|
Other income from
ordinary activities
|
|
|
|
7,279
|
7,940
|
|
6,962
|
7,295
|
Total operating
income
|
|
|
|
15,759
|
16,293
|
|
15,015
|
14,923
|
Personnel expenses
|
|
6
|
|
3,109
|
3,221
|
|
2,960
|
2,943
|
General and
administrative expenses
|
|
7
|
|
3,543
|
3,625
|
|
3,375
|
3,317
|
Subtotal operating
expenses
|
|
|
|
6,653
|
6,846
|
|
6,334
|
6,260
|
Impairment of
investments in subsidiaries and other participations
|
|
4
|
|
1,056
|
1,187
|
|
1,014
|
1,090
|
Depreciation,
amortization and impairment of property, equipment, software and intangible
assets
|
|
|
|
743
|
816
|
|
708
|
747
|
Changes in
provisions for litigation, regulatory and similar matters, and other
provisions
|
|
8
|
|
54
|
862
|
|
50
|
787
|
Total operating
expenses
|
|
|
|
8,505
|
9,712
|
|
8,106
|
8,885
|
Operating profit
|
|
|
|
7,253
|
6,581
|
|
6,909
|
6,037
|
Extraordinary
income
|
|
9
|
|
201
|
282
|
|
191
|
262
|
Extraordinary
expenses
|
|
9
|
|
2
|
1
|
|
2
|
1
|
Tax expense /
(benefit)
|
|
10
|
|
295
|
315
|
|
281
|
286
|
Net profit /
(loss)
|
|
|
|
7,157
|
6,548
|
|
6,817
|
6,013
|
1 Interest income
includes negative interest income of approximately USD 0.4bn (CHF 0.4bn) for
the year ended 31 December 2022 (approximately USD 0.5bn (CHF 0.4bn) for the
year ended 31 December 2021). 2 Includes negative interest expense on
financial liabilities of approximately USD 0.4bn (CHF 0.4bn) for the year
ended 31 December 2022 (approximately USD 0.5bn (CHF 0.4bn) for the year
ended 31 December 2021).
|
UBS AG standalone
financial statements (audited) 1
Balance sheet
|
|
|
|
|
|
|
|
|
|
|
USD m
|
|
CHF m
|
|
|
Note
|
|
31.12.22
|
31.12.21
|
|
31.12.22
|
31.12.21
|
|
|
|
|
|
|
|
|
|
Assets
|
|
|
|
|
|
|
|
|
Cash and balances
at central banks
|
|
13
|
|
48,344
|
53,760
|
|
44,684
|
49,012
|
Due from banks
|
|
13, 24
|
|
31,450
|
33,330
|
|
29,069
|
30,386
|
Receivables from
securities financing transactions
|
|
11, 13, 24
|
|
58,141
|
56,336
|
|
53,739
|
51,360
|
Due from customers
|
|
12, 13, 24
|
|
105,552
|
121,812
|
|
97,561
|
111,052
|
Funding provided
to significant regulated subsidiaries eligible as total loss-absorbing
capacity1
|
|
12, 13, 24
|
|
27,678
|
27,530
|
|
25,582
|
25,098
|
Mortgage loans
|
|
12, 13
|
|
5,039
|
5,492
|
|
4,657
|
5,007
|
Trading portfolio
assets
|
|
14
|
|
98,566
|
119,795
|
|
91,104
|
109,213
|
Derivative
financial instruments
|
|
15
|
|
14,701
|
11,921
|
|
13,588
|
10,868
|
Financial
investments
|
|
16
|
|
43,746
|
19,482
|
|
40,434
|
17,761
|
Accrued income and
prepaid expenses
|
|
13
|
|
1,872
|
1,213
|
|
1,730
|
1,106
|
Investments in
subsidiaries and other participations
|
|
4
|
|
51,029
|
50,671
|
|
47,165
|
46,195
|
Property,
equipment and software
|
|
|
|
5,134
|
5,580
|
|
4,745
|
5,087
|
Other assets
|
|
12, 13, 17
|
|
13,516
|
2,927
|
|
12,491
|
2,667
|
Total assets
|
|
|
|
504,767
|
509,851
|
|
466,550
|
464,814
|
of which:
subordinated assets
|
|
|
|
18,748
|
18,751
|
|
17,329
|
17,095
|
of which: subject
to mandatory conversion and / or debt waiver
|
|
|
|
18,042
|
17,813
|
|
16,676
|
16,239
|
|
|
|
|
|
|
|
|
|
Liabilities
|
|
|
|
|
|
|
|
|
Due to banks
|
|
24
|
|
47,329
|
40,293
|
|
43,745
|
36,734
|
Payables from
securities financing transactions
|
|
11, 24
|
|
23,497
|
23,046
|
|
21,718
|
21,010
|
Due to customers
|
|
24
|
|
138,941
|
141,119
|
|
128,421
|
128,654
|
Funding received
from UBS Group AG measured at amortized cost
|
|
21, 24
|
|
61,202
|
57,078
|
|
56,568
|
52,036
|
Trading portfolio
liabilities
|
|
14
|
|
25,058
|
25,711
|
|
23,160
|
23,440
|
Derivative
financial instruments
|
|
15
|
|
17,429
|
14,128
|
|
16,109
|
12,880
|
Financial
liabilities designated at fair value
|
|
14, 20
|
|
70,603
|
73,081
|
|
65,258
|
66,625
|
of which: funding
received from UBS Group AG
|
|
20, 21, 24
|
|
1,959
|
2,137
|
|
1,811
|
1,948
|
Bonds issued
|
|
21
|
|
56,148
|
73,631
|
|
51,897
|
67,127
|
Accrued expenses
and deferred income
|
|
|
|
3,592
|
2,919
|
|
3,320
|
2,661
|
Other liabilities
|
|
17
|
|
1,582
|
2,305
|
|
1,462
|
2,100
|
Provisions
|
|
13
|
|
2,026
|
2,136
|
|
1,872
|
1,947
|
Total liabilities
|
|
|
|
447,406
|
455,446
|
|
413,532
|
415,215
|
|
|
|
|
|
|
|
|
|
Equity
|
|
|
|
|
|
|
|
|
Share capital
|
|
22
|
|
393
|
393
|
|
386
|
386
|
General reserve
|
|
|
|
36,326
|
36,326
|
|
35,649
|
35,649
|
of which:
statutory capital reserve
|
|
|
|
36,326
|
36,326
|
|
35,649
|
35,649
|
of which: capital
contribution reserve2
|
|
|
|
36,326
|
36,326
|
|
35,649
|
35,649
|
Voluntary earnings
reserve
|
|
|
|
13,485
|
11,138
|
|
10,167
|
7,552
|
Net profit /
(loss) for the period
|
|
|
|
7,157
|
6,548
|
|
6,817
|
6,013
|
Total equity
|
|
|
|
57,361
|
54,405
|
|
53,018
|
49,599
|
Total liabilities
and equity
|
|
|
|
504,767
|
509,851
|
|
466,550
|
464,814
|
of which:
subordinated liabilities
|
|
|
|
66,872
|
65,219
|
|
61,809
|
59,459
|
of which: subject
to mandatory conversion and / or debt waiver
|
|
|
|
66,314
|
64,654
|
|
61,293
|
58,943
|
1 Represents the Swiss GAAP carrying amount of instruments
qualifying as total loss-absorbing capital at the level of the respective
subsidiaries. 2 The Swiss Federal Tax Administration’s current
position is that, of the CHF 35.6bn capital contribution reserve
available as of 31 December 2022, an amount limited to CHF 20.5bn
is available from which dividends may be paid without a Swiss withholding tax
deduction.
|
UBS AG standalone
financial statements (audited) 2
Balance sheet (continued)
|
|
|
|
|
|
|
|
|
USD m
|
|
CHF m
|
|
|
31.12.22
|
31.12.21
|
|
31.12.22
|
31.12.21
|
|
|
|
|
|
|
|
Off-balance sheet items
|
|
|
|
|
|
|
Contingent
liabilities, gross
|
|
20,359
|
19,046
|
|
18,818
|
17,364
|
Sub-participations
|
|
(1,069)
|
(1,093)
|
|
(988)
|
(997)
|
Contingent liabilities,
net
|
|
19,290
|
17,953
|
|
17,830
|
16,367
|
of which:
guarantees to third parties related to subsidiaries
|
|
6,156
|
7,825
|
|
5,690
|
7,133
|
Irrevocable loan
commitments, gross
|
|
16,272
|
17,394
|
|
15,041
|
15,858
|
Sub-participations
|
|
0
|
0
|
|
0
|
0
|
Irrevocable loan commitments,
net
|
|
16,272
|
17,394
|
|
15,041
|
15,858
|
Forward starting
transactions1
|
|
54,321
|
41,719
|
|
50,208
|
38,034
|
of which: reverse
repurchase agreements
|
|
27,343
|
24,559
|
|
25,273
|
22,390
|
of which:
repurchase agreements
|
|
26,978
|
17,160
|
|
24,936
|
15,644
|
Liabilities for
calls on shares and other equity instruments
|
|
5
|
5
|
|
4
|
4
|
1 Cash to be paid in the future by either UBS AG or the
counterparty.
|
Off-balance sheet items
Contingent liabilities include indemnities and
guarantees issued by UBS AG for the benefit of subsidiaries and creditors of
subsidiaries.
Where the indemnity amount issued by UBS AG is not
specifically defined, the indemnity relates to the solvency or minimum
capitalization of a subsidiary, and therefore no amount is included in the table
above.
Joint and several liability – value-added
tax
UBS AG is jointly and severally liable for the
combined value-added tax (VAT) liability of UBS entities that belong to the VAT
group of UBS in Switzerland. This contingent liability is not included in the
table above.
Guarantees – UBS Europe SE
Following the combined UK business transfer and
cross-border merger of UBS Limited into UBS Europe SE in March 2019, UBS AG
issued a guarantee for the benefit of counterparties of UBS Europe SE’s investment
banking business, covering transactions subject to master netting agreements.
A similar guarantee that UBS AG issued in 2003 for the benefit
of each counterparty of UBS Limited also continues to be effective. This
guarantee covers transactions in accordance with and contemplated under any
agreement entered into by UBS Limited prior to the merger into UBS Europe SE,
to the extent that such an agreement has not been amended by UBS Europe SE
thereafter.
Under both guarantees, UBS AG promises to pay to the
beneficiary counterparties any unpaid liabilities covered under the terms of
the guarantees on demand. These guarantees are included as contingent
liabilities in the off-balance sheet items table above.
Indemnities – UBS Europe SE
In connection with the establishing of UBS Europe SE
in 2016, UBS AG entered into agreements with UBS Europe SE under which UBS AG
would provide UBS Europe SE with limited indemnification of payment obligations
that may arise from certain litigation, regulatory and similar matters.
As of 31 December 2022, the amount of such potential
payment obligations could not be reliably estimated and the likelihood of an
outflow is not considered to be probable or the probability of an outflow was
assessed to be remote; therefore, the table above does not include any amount
related to this limited indemnification.
In addition, in accordance with the bylaws of the Deposit
Protection Fund of the Association of German Banks, UBS AG issued an indemnity
in favor of this fund on behalf of UBS Europe SE. The probability of an outflow
was assessed to be remote, and as a result, the table above does not include
any exposure arising under this indemnity.
UBS AG standalone
financial statements (audited) 3
Statement of changes in equity
|
|
|
|
|
|
USD m
|
Share capital
|
Statutory capital reserve
|
Voluntary earnings
reserve and
profit / (loss)
carried forward
|
Net profit / (loss)
for the period
|
Total equity
|
|
|
|
|
|
|
Balance as of 1
January 2022
|
393
|
36,326
|
11,138
|
6,548
|
54,405
|
Dividend
distribution
|
|
|
(4,200)
|
|
(4,200)
|
Net profit / (loss)
appropriation
|
|
|
6,548
|
(6,548)
|
0
|
Net profit /
(loss) for the period
|
|
|
|
7,157
|
7,157
|
Balance as of 31
December 2022
|
393
|
36,326
|
13,485
|
7,157
|
57,361
|
CHF m
|
Share capital
|
Statutory capital reserve
|
Voluntary earnings
reserve and
profit / (loss)
carried forward
|
Net profit / (loss)
for the period
|
Total equity
|
|
|
|
|
|
|
Balance as of 1
January 2022
|
386
|
35,649
|
7,552
|
6,013
|
49,599
|
Dividend
distribution
|
|
|
(4,087)
|
|
(4,087)
|
Net profit /
(loss) appropriation
|
|
|
6,013
|
(6,013)
|
0
|
Net profit /
(loss) for the period
|
|
|
|
6,817
|
6,817
|
Currency
translation difference
|
|
|
690
|
|
690
|
Balance as of 31
December 2022
|
386
|
35,649
|
10,167
|
6,817
|
53,018
|
Statement of proposed
appropriation of total profit and dividend distribution
The Board of Directors (the BoD) proposes that the
Annual General Meeting of Shareholders (the AGM) on 4 April 2023 approve
the appropriation of total profit and an ordinary dividend distribution of
USD 6,000m out of the total profit as follows:
Appropriation of and distribution out of total profit
|
|
|
USD m
|
|
CHF m
|
|
|
For the year ended
|
|
For the year ended
|
|
|
31.12.22
|
|
31.12.22
|
Net profit for the
period
|
|
7,157
|
|
6,817
|
Profit / (loss)
carried forward
|
|
0
|
|
0
|
Total profit
available for appropriation
|
|
7,157
|
|
6,817
|
Appropriation to voluntary
earnings reserve
|
|
(1,157)
|
|
(1,271)
|
Dividend
distribution
|
|
(6,000)
|
|
(5,546)1
|
Profit / (loss)
carried forward
|
|
0
|
|
0
|
1 For illustrative purposes, converted at closing exchange rate
as of 31 December 2022 (CHF / USD 1.08).
|
The ordinary dividend distribution is declared and
paid in US dollars. The total amount of the dividend distribution is capped at
CHF 12,000m (the Cap). To the extent that the Swiss franc equivalent of
the total dividend distribution of USD 6,000m would exceed the Cap on the
day of the AGM, based on the exchange rate determined by the BoD in its
reasonable opinion, the US dollar per share amount of the dividend will be
reduced on a pro rata basis so that the total Swiss franc amount does not
exceed the Cap. To the extent the Swiss franc equivalent of the total dividend
distribution exceeds CHF 6,817m but does not exceed the Cap, the total
dividend distribution in US dollars remains as is and is booked against the
total profit in US dollars, while the Swiss franc currency difference of
maximum CHF 5,183m is balanced through the Swiss franc translation of the
voluntary earnings reserve account.
UBS AG standalone
financial statements (audited) 4
Note 1 Name,
legal form and registered office
UBS AG is incorporated and domiciled in Switzerland.
Its registered offices are at Bahnhofstrasse 45, CH-8001 Zurich and
Aeschenvorstadt 1, CH-4051 Basel, Switzerland. UBS AG operates under Art. 620
et seq. of the Swiss Code of Obligations and Swiss banking law as an Aktiengesellschaft,
a corporation limited by shares.
UBS AG is a regulated bank in Switzerland and is 100% owned by
UBS Group AG, the ultimate parent of the UBS Group. UBS AG holds investments in
and provides funding to subsidiaries, including the other banking subsidiaries
of the UBS Group. In addition, UBS AG operates globally, including business
activities from all four UBS business divisions and Group Functions. In the
ordinary course of business, the main contributors to the net profit / (loss)
of UBS AG are the Investment Bank, Global Wealth Management, Group Treasury and
Group Services. The balance sheet is mainly composed of financial assets and
liabilities from the Investment Bank, Group Treasury and Global Wealth
Management businesses booked outside of Switzerland, as well as investments in
subsidiaries and other participations in Group Treasury and fixed assets of Group
Services.
UBS AG employed 10,333 personnel on a full-time equivalent
basis as of 31 December 2022, compared with 10,169 personnel as of
31 December 2021.
Note 2 Accounting policies
a) Significant accounting
policies
UBS AG standalone financial statements are prepared in
accordance with Swiss GAAP (the FINMA Accounting Ordinance, FINMA Circular
2020/1 “Accounting – banks” and the Banking Ordinance) and represent “reliable
assessment statutory single-entity financial statements.” The accounting
policies are principally the same as those outlined in Note 1 to the
consolidated financial statements of UBS AG included in the UBS Group AG and
UBS AG Annual Report 2022. Major differences between the Swiss GAAP
requirements and International Financial Reporting Standards (IFRS) are
described in Note 33 to the consolidated financial statements of UBS AG. The
significant accounting policies applied for the standalone financial statements
of UBS AG are discussed below.
› Refer to the UBS Group AG and UBS AG Annual Report 2022 for more
information
Risk management
UBS AG is fully integrated into the Group-wide risk
management process described in the audited part of the “Risk management and
control” section of the UBS Group AG and UBS AG Annual Report 2022.
Further information about the use of derivative instruments
and hedge accounting is provided on the following pages and in Notes 1, 10 and
25 to the consolidated financial statements of UBS AG.
› Refer to the UBS Group AG and UBS AG Annual Report 2022 for more
information
Compensation policy
The compensation structure and processes of UBS AG
conform to the compensation principles and framework of UBS Group AG. For
detailed information, refer to the Compensation Report of UBS Group AG.
Deferred compensation
Expenses for deferred compensation awards granted by
UBS Group AG to employees of UBS AG in the form of UBS shares, notional
investment funds and notional additional tier 1 (AT1) capital instruments are
charged by UBS Group AG to UBS AG.
› Refer to Note 27 to the UBS AG consolidated financial statements
in the UBS Group AG and UBS AG Annual Report 2022 for more information
Foreign currency translation
Non-US dollar-denominated transactions are translated
into US dollars at the spot exchange rate on the date of the transaction. At
the balance sheet date, all non-US dollar-denominated monetary assets and
liabilities, as well as non-US dollar-denominated equity instruments recorded
in Trading portfolio assets and Financial investments, are translated
into US dollars using the closing exchange rate. Non-monetary items measured at
historic cost are translated at the spot exchange rate on the date of the
transaction. Assets and liabilities of branches with functional currencies
other than the US dollar are translated into US dollars at the closing exchange
rate. Income and expense items of such branches are translated at weighted-average
exchange rates for the period. All currency translation effects are recognized
in the income statement.
The main currency translation rates used by UBS AG are
provided in Note 32 of the consolidated financial statements of UBS AG.
› Refer to the UBS Group AG and UBS AG Annual Report 2022 for more
information
UBS AG standalone
financial statements (audited) 5
Note 2 Accounting
policies (continued)
Presentation currencies
As the primary presentation currency of the financial
statements of UBS AG is the US dollar, amounts in Swiss francs are additionally
presented for each component of the financial statements. UBS AG applies the
modified closing rate method for converting the US dollar presentation currency
amounts into Swiss francs: assets and liabilities are converted at the closing
rate, equity positions at historic rates, and income and expense items at the
weighted-average rate for the period. The resulting currency translation
effects are recognized separately in the Voluntary earnings reserve,
amounting to a negative currency translation effect of CHF 2,929m as of
31 December 2022 (negative CHF 3,619m as of 31 December 2021).
Structured debt instruments
Structured debt instruments consist of debt
instruments issued and transacted over the counter and include a host contract
and one or more embedded derivatives that do not relate to UBS AG’s own equity.
By applying the fair value option, the vast majority of structured debt
instruments are measured at fair value as a whole and recognized
in Financial liabilities designated at fair value.
The fair value option for structured debt instruments can be applied only if
the following criteria are cumulatively met:
– the
structured debt instrument is measured on a fair value basis and is subject to
risk management that is equivalent to risk management for trading activities;
– the
application of the fair value option eliminates or significantly reduces an
accounting mismatch that would otherwise arise; and
– changes
in fair value attributable to changes in unrealized own credit are not
recognized.
Fair value changes related to Financial
liabilities designated at fair value, excluding changes in unrealized
own credit, are recognized in Net trading income. Interest
expense on Financial liabilities designated at fair value is
recognized in Interest expense.
Where the designation criteria for the fair value option are
not met, the embedded derivatives are assessed for bifurcation for measurement
purposes. Bifurcated embedded derivatives are measured at fair value through
profit or loss and presented in the same balance sheet line as the host
contract.
› Refer to Note 20 for more information
Group-internal funding
UBS AG obtains funding from UBS Group AG in the form
of loans that are subject to mandatory conversion and / or debt waiver, as
explained below, and generally either qualify as loss-absorbing tier 1 capital
or as gone concern loss-absorbing capacity, i.e., total funding eligible as
total loss-absorbing capacity (TLAC), at the UBS AG consolidated and standalone
levels. A portion of Group-internal funding obtained is further on lent by UBS
AG to certain subsidiaries in the form of loans.
› Refer to Note 21 for information about funding eligible as total
loss-absorbing capacity at the UBS AG level
UBS AG obligations arising from Group-internal funding it has
received are presented as Funding received from UBS Group AG measured at
amortized cost and Funding received from UBS Group AG within Financial
liabilities designated at fair value. UBS AG claims arising from
Group-internal funding it has provided are presented as Funding provided to
significant regulated subsidiaries eligible as total loss-absorbing capacity
and are measured at amortized cost less any allowance for expected credit
losses.
Subordinated assets and liabilities
Subordinated assets are composed of claims that, based
on an irrevocable written declaration, in the event of liquidation, bankruptcy
or composition concerning the debtor, rank after the claims of all other
creditors and may not be offset against amounts payable to the debtor nor be
secured by its assets. Subordinated liabilities are composed of
corresponding obligations.
Subordinated assets and liabilities that contain a
point-of-non-viability clause in accordance with Swiss capital requirements
pursuant to Art. 29 and 30 of the Capital Adequacy Ordinance are disclosed as
being Subject to mandatory conversion and / or debt waiver and provide
for the claim or the obligation to be written off or converted into equity in
the event that the issuing bank reaches a point of non-viability.
UBS AG standalone
financial statements (audited) 6
Note 2 Accounting
policies (continued)
Investments in subsidiaries and other participations
Investments in subsidiaries and
other participations are equity interests that are held to carry on the
business of UBS AG or for other strategic purposes. They include all
subsidiaries directly held by UBS AG through which UBS AG conducts its business
on a global basis. The investments are measured individually and carried at
cost less impairment. The carrying amount is tested for impairment annually and
when indicators of a potential decrease in value exist, which include
significant operating losses incurred or a severe depreciation of the currency
in which the investment is denominated. If an investment in a subsidiary is
impaired, its value is generally written down to the net asset value.
Subsequent recoveries in value are recognized up to the original cost value
based on either the increased net asset value or a value above the net asset
value if, in the opinion of management, forecasts of future profitability
provide sufficient evidence that a carrying amount above net asset value is
supported. Management may exercise its discretion as to what extent and in
which period a recovery in value is recognized.
Impairments of investments are presented as
Impairment of investments in subsidiaries and other participations and reversals
of impairments are presented as Extraordinary
income in the income statement. Impairments and partial or full
reversals of impairments for a subsidiary during the same annual period are
determined on a net basis.
› Refer to Note 4 for more information
Hedge accounting for Investments in subsidiaries and
other participations
UBS AG applies hedge accounting for certain
investments in subsidiaries and other participations denominated in currencies
other than the US dollar, which are designated as hedged items. For this
purpose, foreign exchange (FX) derivatives, mainly FX forwards and FX swaps,
are used and designated as hedging instruments.
The hedged risk is determined as the change in the carrying
amount of the hedged item arising solely from changes in spot FX rates.
Consequently, UBS AG only designates the spot element of the FX derivatives as
hedging instruments. Changes in the fair value of the hedging instruments
attributable to changes in forward points are not part of a hedge accounting
designation. These amounts, therefore, do not form part of the effectiveness
assessment and are recognized in Net trading income.
The effective portion of gains and losses of these FX
derivatives is deferred on the balance sheet as Other assets or Other
liabilities to the extent no change is recognized in the carrying amount of
the hedged item arising from changes in spot FX rates. Otherwise, the effective
portion of gains and losses of these FX derivatives is matched with the
corresponding valuation adjustments of the hedged item recorded in the income
statement and recorded either as a reduction of Impairment of investments in
subsidiaries and other participations or as Extraordinary income.
Revenue and expense transfers with
other Group entities
UBS AG pays to and receives amounts from other Group
entities in connection with revenue sharing arrangements, primarily related to
the Investment Bank. Revenues transferred to and received from Group entities
are settled in cash as hard revenue transfers paid or received. When the nature
of the underlying transaction between UBS AG and the Group entity contains a
single, clearly identifiable service component, related income and expenses are
presented in the respective income statement line item, e.g., Fee and
commission income from securities and investment business and other fee and
commission income, Fee and commission expense or Net trading
income. To the extent the nature of the underlying transaction contains
various service components and is not clearly attributable to a particular
income statement line item, related income and expenses are presented in Sundry
ordinary income and Sundry ordinary expenses.
UBS AG receives services from UBS Business Solutions AG, the
main Group service company, mainly relating to the Chief Digital and
Information Office, as well as certain other services from other Group
entities.
UBS AG provides services to Group entities, mainly relating to
real estate and selected other Group Services functions.
Services received from and provided to Group entities are
settled in cash as hard cost transfers paid or received. Hard cost transfers
paid are presented within General and administrative expenses and hard
cost transfers received are presented within Sundry ordinary income or Income
from real estate holdings.
› Refer to Notes 5 and 7 for more information
UBS AG standalone
financial statements (audited) 7
Note 2
Accounting policies (continued)
Post-employment benefit plans
Swiss GAAP permit the use of IFRS or Swiss accounting
standards for post-employment benefit plans, with the election made on a
plan-by-plan basis.
UBS AG has elected to apply Swiss GAAP (FER 16) for the
Swiss pension plan in its standalone financial statements. The requirements of
Swiss GAAP (FER 16) are better aligned with the specific nature of Swiss
pension plans, which are hybrid in that they combine elements of defined
contribution and defined benefit plans but are treated as defined benefit plans
under IFRS. Swiss GAAP (FER 16) require that the employer contributions to the
pension fund are recognized as Personnel expenses in the income statement. The employer
contributions to the Swiss pension fund are determined as a percentage of
contributory compensation. Furthermore, Swiss GAAP (FER16) require an
assessment as to whether, based on the financial statements of the pension fund
prepared in accordance with Swiss accounting standards (FER 26), an
economic benefit to, or obligation of, UBS AG arises from the pension fund that
is recognized in the balance sheet when conditions are met. Conditions for
recording a pension asset or liability would be met if, for example, an
employer contribution reserve is available or UBS AG is required to
contribute to the reduction of a pension deficit (on an FER 26 basis).
Key differences between Swiss GAAP (FER 16) and IFRS include
the treatment of dynamic elements, such as future salary increases and future
interest credits on retirement savings, which are not considered under the
static method used in accordance with Swiss GAAP (FER 16). Also, the discount
rate used to determine the defined benefit obligation in accordance with IFRS
is based on the yield of high-quality corporate bonds of the market in the
respective pension plan country. The discount rate used in accordance with
Swiss GAAP (FER 16), i.e., the technical interest rate, is determined by the
Pension Foundation Board, based on the expected returns of the Board’s
investment strategy.
› Refer to Note 23 for more information
UBS AG has elected to apply IFRS (IAS 19) for its
non-Swiss defined benefit plans. However, remeasurements of the defined benefit
obligation and the plan assets are recognized in the income statement rather
than directly in equity. For corresponding disclosures in accordance with IAS 19
requirements, refer to Note 26 to the consolidated financial statements of
UBS AG.
› Refer to the UBS Group AG and UBS AG Annual Report 2022 for more
information
Deferred taxes
Deferred tax assets are not recognized in UBS AG’s standalone
financial statements. However, deferred tax liabilities may be recognized for
taxable temporary differences. Changes in the deferred tax liability balance
are recognized in the income statement.
Allowances and provisions for expected credit losses
UBS AG is required to apply expected credit loss (ECL)
approaches for credit-impaired and non-credit-impaired financial instruments in
its standalone financial statements.
For the substantial majority of non-credit-impaired exposures within
the scope of the Swiss GAAP ECL requirements, UBS AG has chosen to apply
the IFRS ECL approach that is also applied in its consolidated financial
statements. These exposures include all financial assets that are measured at
amortized cost under both frameworks, Swiss GAAP and IFRS, fee and lease
receivables, claims arising from Group-internal funding presented as Funding
provided to significant regulated subsidiaries eligible as total loss-absorbing
capacity, guarantees, irrevocable loan commitments, revolving revocable
credit lines and forward starting reverse repurchase and securities borrowing
agreements. Further information about the ECL approach under IFRS is provided
in Note 1 to the consolidated financial statements of UBS AG.
› Refer to the UBS Group AG and UBS AG Annual Report 2022 for more
information
For the small residual population of exposures within the
scope of the Swiss GAAP ECL requirements, which are not subject to ECL under
IFRS due to classification differences, alternative approaches are applied.
·
For exposures for which Pillar 1 internal
ratings-based models are applied for measurement of credit risk RWA, ECL for
such exposures is calculated as the regulatory expected loss (EL), with an
add-on to scale up to the residual maturity of exposures maturing beyond the
next 12 months. This approach is mainly applied for brokerage receivables
presented within Due from customers, which generally mature
within 12 months. For detailed information about regulatory EL, refer to the
“Risk management and control” section of the UBS Group AG and UBS AG Annual
Report 2022.
·
For exposures for which the standardized
approach is applied for the measurement of credit risk RWA, ECL is determined
using a portfolio approach that derives a conservative probability of default (“PD”)
and a conservative loss given default (“LGD”) for the entire portfolio. This
approach is mainly applied for a small number of loans to large corporate
clients presented within Due from customers.
UBS AG standalone
financial statements (audited) 8
Note 2
Accounting policies (continued)
UBS applies a single definition of default for credit risk
management purposes, regulatory reporting and ECL, with a counterparty
classified as defaulted based on quantitative and qualitative criteria.
› Refer to “Credit policies for distressed assets” in the “Risk
management and control” section of the UBS Group AG Annual Report 2022 for more
information
An allowance for credit losses is reported as a decrease in
the carrying amount of a financial asset. For an off-balance sheet item, such
as a commitment, a provision for credit losses is reported in Provisions.
Changes to allowances and provisions for credit losses are recognized in Credit
loss (expense) / release.
› Refer to Note 13 for more information
Dispensations in the standalone financial statements
As UBS AG prepares consolidated financial statements in
accordance with IFRS, UBS AG is exempt from various disclosures in the
standalone financial statements. The dispensations include the management
report, the statement of cash flows and various note disclosures, as well as
the publication of full interim financial statements. As a Swiss issuer of
debt, in order to validly issue debt throughout the year, UBS AG discloses
interim mid-year financial information as per the requirements of Art. 1156 of
the Swiss Code of Obligations in conjunction with Art. 652a thereof, including
an income statement, a balance sheet and a note on the basis of accounting.
b) Changes in accounting
policies
There were no significant changes in accounting
policies during 2022.
Note 3a Net
trading income by business
|
|
USD m
|
|
CHF m
|
|
|
For the year ended
|
|
For the year ended
|
|
|
31.12.22
|
31.12.21
|
|
31.12.22
|
31.12.21
|
Investment Bank
|
|
5,271
|
3,588
|
|
5,016
|
3,263
|
of which: Global
Markets
|
|
5,423
|
3,632
|
|
5,165
|
3,303
|
of which: Global
Banking
|
|
(152)
|
(44)
|
|
(148)
|
(40)
|
Other business
divisions and Group Functions
|
|
525
|
35
|
|
496
|
38
|
Total net trading
income
|
|
5,796
|
3,623
|
|
5,512
|
3,301
|
2021 included a loss of USD 861m
(CHF 811m) incurred in the first half of 2021 in the Investment Bank on a
default by a US-based client of UBS AG’s prime brokerage business.
Note 3b Net trading
income by underlying risk category
|
|
USD m
|
|
CHF m
|
|
|
For the year ended
|
|
For the year ended
|
|
|
31.12.22
|
31.12.21
|
|
31.12.22
|
31.12.21
|
Equity instruments
(including funds)
|
|
3,528
|
2,283
|
|
3,361
|
2,069
|
Foreign exchange
instruments
|
|
1,404
|
978
|
|
1,341
|
896
|
Interest rate and
credit instruments (including funds)
|
|
763
|
310
|
|
714
|
290
|
Other
|
|
100
|
51
|
|
97
|
47
|
Total net trading
income
|
|
5,796
|
3,623
|
|
5,512
|
3,301
|
of which: net
gains / (losses) from financial liabilities designated at fair value 1
|
|
12,687
|
(4,318)
|
|
12,184
|
(3,929)
|
1 Excludes fair value changes of hedges related to financial
liabilities designated at fair value and foreign currency effects arising
from translating foreign currency transactions into the respective functional
currency, both of which are reported within Net trading income.
|
UBS AG standalone
financial statements (audited) 9
Note 4 Investments in subsidiaries and other participations
The table below provides the carrying amount, the
equity interest and the registered office information regarding the investments
in subsidiaries and other participations.
|
Registered office
|
Equity interest accumulated in %
|
|
Carrying amount in USD m
|
|
Carrying amount in CHF m
|
|
|
|
|
31.12.22
|
31.12.21
|
|
31.12.22
|
31.12.21
|
UBS Americas
Holding LLC
|
Wilmington,
Delaware, USA
|
100
|
|
34,233
|
33,233
|
|
31,642
|
30,297
|
UBS Switzerland AG
|
Zurich,
Switzerland
|
100
|
|
7,984
|
7,983
|
|
7,380
|
7,278
|
UBS Europe SE
|
Frankfurt, Germany
|
100
|
|
3,572
|
3,946
|
|
3,301
|
3,597
|
UBS Asset
Management AG
|
Zurich,
Switzerland
|
100
|
|
1,728
|
1,726
|
|
1,597
|
1,573
|
Other
|
|
|
|
3,511
|
3,784
|
|
3,246
|
3,449
|
Total investments
in subsidiaries and other participations
|
|
|
|
51,029
|
50,671
|
|
47,165
|
46,195
|
|
Dividend income from
investments in subsidiaries and other participations of USD 6,465m
(CHF 6,183m) in 2022 and USD 6,401m (CHF 5,882m) in 2021 was
mainly attributable to UBS Americas Holding LLC, UBS Switzerland AG,
UBS Asset Management AG and UBS Europe SE.
In 2022 and 2021, UBS AG recognized Impairments
of investments in subsidiaries and other participations of USD 1,056m
(CHF 1,014m) and USD 1,187m (CHF 1,090m), respectively, mainly
due to impairments related to UBS Europe SE (2022: USD 628m
(CHF 609m), 2021: USD 1,063m (CHF 973m)), which partly offset
the dividends received from this subsidiary.
Note 5 Sundry
ordinary income and expenses
|
|
USD m
|
|
CHF m
|
|
|
For the year ended
|
|
For the year ended
|
|
|
31.12.22
|
31.12.21
|
|
31.12.22
|
31.12.21
|
Income from
services provided to UBS Group AG or its subsidiaries1
|
|
1,398
|
1,312
|
|
1,332
|
1,201
|
Other
|
|
69
|
30
|
|
65
|
28
|
Total sundry
ordinary income
|
|
1,467
|
1,342
|
|
1,397
|
1,229
|
Expenses from
revenue transfers to UBS Group AG or its subsidiaries
|
|
(629)
|
(289)
|
|
(596)
|
(262)
|
Net unrealized
losses on financial investments2
|
|
(288)
|
(38)
|
|
(274)
|
(35)
|
Other
|
|
(20)
|
(11)
|
|
(19)
|
(10)
|
Total sundry
ordinary expenses
|
|
(937)
|
(338)
|
|
(888)
|
(308)
|
1 Services provided by UBS AG primarily related to Group
Functions. 2 Mainly relates to debt instruments available for sale. Refer
to Note 16a for more information.
|
Note 6
Personnel expenses
|
|
USD m
|
|
CHF m
|
|
|
For the year ended
|
|
For the year ended
|
|
|
31.12.22
|
31.12.21
|
|
31.12.22
|
31.12.21
|
Salaries
|
|
1,602
|
1,710
|
|
1,527
|
1,566
|
Variable
compensation – performance awards
|
|
1,141
|
1,158
|
|
1,084
|
1,060
|
Variable
compensation – other
|
|
76
|
53
|
|
72
|
48
|
Contractors
|
|
35
|
51
|
|
33
|
47
|
Social security
|
|
205
|
216
|
|
194
|
198
|
Post-employment
benefit plans
|
|
(55)
|
(74)
|
|
(51)
|
(73)
|
of which: value
adjustments for economic benefits or obligations from non-Swiss pension funds
1
|
|
(167)
|
(208)
|
|
(157)
|
(195)
|
Other personnel
expenses
|
|
106
|
106
|
|
101
|
97
|
Total personnel
expenses
|
|
3,109
|
3,221
|
|
2,960
|
2,943
|
1 Reflects the remeasurement of the defined benefit obligation
and return on plan assets excluding amounts included in interest income for
the non-Swiss defined benefit plans, for which IAS 19 is applied.
|
UBS AG standalone
financial statements (audited) 10
Note 7 General
and administrative expenses
|
|
USD m
|
|
CHF m
|
|
|
For the year ended
|
|
For the year ended
|
|
|
31.12.22
|
31.12.21
|
|
31.12.22
|
31.12.21
|
Real estate
|
|
415
|
461
|
|
395
|
422
|
Market data
services
|
|
108
|
108
|
|
103
|
99
|
IT expenses
|
|
92
|
90
|
|
87
|
83
|
Outsourcing costs
|
|
77
|
83
|
|
74
|
76
|
Marketing and
communication
|
|
27
|
29
|
|
26
|
27
|
Travel and
entertainment
|
|
41
|
18
|
|
39
|
16
|
Fees to audit
firms
|
|
14
|
13
|
|
13
|
12
|
of which:
financial and regulatory audits
|
|
11
|
11
|
|
10
|
10
|
of which:
audit-related services
|
|
3
|
2
|
|
3
|
2
|
of which: tax and
other services
|
|
0
|
0
|
|
0
|
0
|
Other professional
fees
|
|
96
|
108
|
|
92
|
99
|
Other
|
|
2,674
|
2,715
|
|
2,546
|
2,484
|
of which: shared
services costs charged by UBS Group AG or its subsidiaries
|
|
2,465
|
2,524
|
|
2,349
|
2,310
|
Total general and
administrative expenses
|
|
3,543
|
3,625
|
|
3,375
|
3,317
|
|
Note 8
Changes in provisions for litigation, regulatory and similar matters, and other
provisions
Net expenses for provisions for litigation, regulatory and
similar matters, and other provisions were USD 54m (CHF 50m) in 2022, compared
with USD 862m (CHF 787m) in 2021, mainly as 2021 included a USD 755m (CHF 688m)
increase in litigation provisions for the French cross-border matter.
› Refer to Note 17 to the UBS AG consolidated financial
statements in the UBS Group AG and UBS AG Annual Report 2022 for more
information
Note 9
Extraordinary income and expenses
|
|
USD m
|
|
CHF m
|
|
|
For the year ended
|
|
For the year ended
|
|
|
31.12.22
|
31.12.21
|
|
31.12.22
|
31.12.21
|
Reversal of
impairments of and provisions for subsidiaries and other participations1
|
|
5
|
161
|
|
4
|
151
|
Net gains from
disposals of properties
|
|
80
|
114
|
|
74
|
104
|
Gains from
disposals of subsidiaries and other participations
|
|
116
|
2
|
|
113
|
2
|
Other extraordinary
income
|
|
1
|
5
|
|
0
|
5
|
Total
extraordinary income
|
|
201
|
282
|
|
191
|
262
|
Total
extraordinary expenses
|
|
2
|
1
|
|
2
|
1
|
1 Refer to Note 4 for more information.
|
Net gains from disposals of
properties of USD 80m (CHF 74m) in 2022 and of USD 114m
(CHF 104m) in 2021 mainly reflected gains on the sale of properties in
Basel.
Gains from disposals of subsidiaries and other
participations of USD 116m (CHF 113m) in 2022 mainly included a gain from
the sale of UBS AG’s wholly owned subsidiary UBS Swiss Financial Advisers AG to
Vontobel.
UBS AG standalone
financial statements (audited) 11
|
|
USD m
|
|
CHF m
|
|
|
For the year ended
|
|
For the year ended
|
|
|
31.12.22
|
31.12.21
|
|
31.12.22
|
31.12.21
|
Income tax expense
/ (benefit)
|
|
271
|
307
|
|
258
|
279
|
of which: current
|
|
250
|
282
|
|
237
|
256
|
of which: deferred
|
|
21
|
25
|
|
21
|
23
|
Capital tax
|
|
24
|
8
|
|
23
|
7
|
Total tax expense
/ (benefit)
|
|
295
|
315
|
|
281
|
286
|
Income tax expense of USD 271m (CHF
258m) was recognized for UBS AG in 2022, compared with USD 307m (CHF 279m)
for 2021. The income tax expense for 2022 was reduced by a benefit of USD 204m
(CHF 195m) in respect of the utilization of tax losses carried forward,
primarily in the US and the UK. The income tax expense for 2022 related to UBS AG’s
taxable profits that were primarily earned in other locations.
The income tax expense for 2021 was reduced by a benefit of
USD 163m (CHF 149m) in respect of the utilization of tax losses
carried forward, primarily in the US. The income tax expense for 2021 related
to UBS AG’s taxable profits that were earned in other locations.
For 2022, the average tax rate, defined as income tax expense
divided by the sum of operating profit and extraordinary income minus
extraordinary expenses and capital tax, was 3.6% (2021: 4.5%).
Note 11
Securities financing transactions
|
|
USD bn
|
|
CHF bn
|
|
|
31.12.22
|
31.12.21
|
|
31.12.22
|
31.12.21
|
|
|
|
|
|
|
|
On-balance sheet
|
|
|
|
|
|
|
Receivables from
securities financing transactions, gross
|
|
131.3
|
139.9
|
|
121.4
|
127.6
|
Netting of
securities financing transactions
|
|
(73.2)
|
(83.6)
|
|
(67.7)
|
(76.2)
|
Receivables from
securities financing transactions, net
|
|
58.1
|
56.3
|
|
53.7
|
51.4
|
|
|
|
|
|
|
|
Payables from
securities financing transactions, gross
|
|
96.7
|
106.6
|
|
89.4
|
97.2
|
Netting of
securities financing transactions
|
|
(73.2)
|
(83.6)
|
|
(67.7)
|
(76.2)
|
Payables from
securities financing transactions, net
|
|
23.5
|
23.0
|
|
21.7
|
21.0
|
|
|
|
|
|
|
|
Assets pledged as
collateral in connection with securities financing transactions
|
|
54.0
|
58.8
|
|
49.9
|
53.6
|
of which: trading
portfolio assets
|
|
50.9
|
57.0
|
|
47.1
|
52.0
|
of which: assets
that may be sold or repledged by counterparties
|
|
39.3
|
47.3
|
|
36.4
|
43.1
|
of which:
financial investments
|
|
3.1
|
1.8
|
|
2.8
|
1.6
|
of which: assets
that may be sold or repledged by counterparties
|
|
2.8
|
1.8
|
|
2.6
|
1.6
|
|
|
|
|
|
|
|
Off-balance sheet
|
|
|
|
|
|
|
Fair value of
assets received as collateral in connection with securities financing
transactions
|
|
312.8
|
343.5
|
|
289.1
|
313.2
|
of which:
repledged
|
|
225.6
|
248.0
|
|
208.5
|
226.1
|
of which: sold in
connection with short sale transactions
|
|
25.1
|
25.7
|
|
23.2
|
23.4
|
UBS AG standalone
financial statements (audited) 12
Note 12a Collateral for loans and off-balance sheet transactions
|
|
31.12.22
|
|
31.12.21
|
|
|
Secured
|
|
Unsecured
|
|
Total
|
|
Secured
|
|
Unsecured
|
|
Total
|
|
|
Secured by collateral
|
|
Secured by
other credit
enhancements2
|
|
|
|
|
|
Secured by collateral
|
|
Secured by
other credit
enhancements2
|
|
|
|
|
USD m
|
|
Real estate
|
|
Other
collateral1
|
|
|
|
|
|
|
Real estate
|
|
Other
collateral1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
On-balance sheet
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Due from
customers, gross3
|
|
7
|
|
64,475
|
|
176
|
|
41,0694
|
|
105,726
|
|
4
|
|
85,928
|
|
192
|
|
35,9014
|
|
122,025
|
Mortgage loans,
gross
|
|
5,039
|
|
|
|
|
|
|
|
5,039
|
|
5,496
|
|
|
|
|
|
|
|
5,496
|
of which:
residential mortgages
|
|
3,205
|
|
|
|
|
|
|
|
3,205
|
|
4,233
|
|
|
|
|
|
|
|
4,233
|
of which: other
mortgages5
|
|
1,834
|
|
|
|
|
|
|
|
1,834
|
|
1,263
|
|
|
|
|
|
|
|
1,263
|
Funding provided
to significant regulated subsidiaries eligible as total loss-absorbing
capacity
|
|
|
|
|
|
|
|
27,704
|
|
27,704
|
|
|
|
|
|
|
|
27,561
|
|
27,561
|
Total on-balance
sheet, gross
|
|
5,045
|
|
64,475
|
|
176
|
|
68,772
|
|
138,469
|
|
5,500
|
|
85,928
|
|
192
|
|
63,463
|
|
155,083
|
Allowances
|
|
0
|
|
(54)
|
|
0
|
|
(145)
|
|
(200)
|
|
(4)
|
|
(78)
|
|
0
|
|
(167)
|
|
(249)
|
Total on-balance
sheet, net
|
|
5,045
|
|
64,421
|
|
176
|
|
68,627
|
|
138,269
|
|
5,496
|
|
85,850
|
|
192
|
|
63,296
|
|
154,834
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Off-balance sheet
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contingent
liabilities, gross
|
|
0
|
|
10,437
|
|
1,069
|
|
8,853
|
|
20,359
|
|
0
|
|
8,190
|
|
1,093
|
|
9,762
|
|
19,046
|
Irrevocable
commitments, gross
|
|
237
|
|
7,467
|
|
129
|
|
8,440
|
|
16,272
|
|
253
|
|
8,192
|
|
226
|
|
8,723
|
|
17,394
|
Forward starting
reverse repurchase and securities borrowing transactions
|
|
|
|
27,343
|
|
|
|
0
|
|
27,343
|
|
|
|
24,559
|
|
|
|
0
|
|
24,559
|
Liabilities for
calls on shares and other equities
|
|
|
|
|
|
|
|
5
|
|
5
|
|
|
|
|
|
|
|
5
|
|
5
|
Total off-balance
sheet
|
|
237
|
|
45,246
|
|
1,198
|
|
17,298
|
|
63,979
|
|
253
|
|
40,941
|
|
1,320
|
|
18,490
|
|
61,005
|
1 Mainly includes cash and securities. 2 Includes
guarantees. 3 Includes prime brokerage margin lending receivables and
prime brokerage receivables relating to securities financing transactions.
4 Primarily consists of amounts due from subsidiaries and other Group
entities. 5 Consists of office and business premises, industrial premises
and other mortgages.
|
|
|
31.12.22
|
|
31.12.21
|
|
|
Secured
|
|
Unsecured
|
|
Total
|
|
Secured
|
|
Unsecured
|
|
Total
|
|
|
Secured by collateral
|
|
Secured by
other credit
enhancements2
|
|
|
|
|
|
Secured by collateral
|
|
Secured by
other credit
enhancements2
|
|
|
|
|
CHF m
|
|
Real estate
|
|
Other
collateral1
|
|
|
|
|
|
|
Real estate
|
|
Other
collateral1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
On-balance sheet
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Due from
customers, gross3
|
|
6
|
|
59,594
|
|
163
|
|
37,9594
|
|
97,722
|
|
4
|
|
78,338
|
|
175
|
|
32,7304
|
|
111,247
|
Mortgage loans,
gross
|
|
4,657
|
|
|
|
|
|
|
|
4,657
|
|
5,011
|
|
|
|
|
|
|
|
5,011
|
of which:
residential mortgages
|
|
2,962
|
|
|
|
|
|
|
|
2,962
|
|
3,859
|
|
|
|
|
|
|
|
3,859
|
of which: other
mortgages5
|
|
1,695
|
|
|
|
|
|
|
|
1,695
|
|
1,151
|
|
|
|
|
|
|
|
1,151
|
Funding provided
to significant regulated subsidiaries eligible as total loss-absorbing
capacity
|
|
|
|
|
|
|
|
25,606
|
|
25,606
|
|
|
|
|
|
|
|
25,127
|
|
25,127
|
Total on-balance
sheet, gross
|
|
4,663
|
|
59,594
|
|
163
|
|
63,565
|
|
127,985
|
|
5,014
|
|
78,338
|
|
175
|
|
57,857
|
|
141,384
|
Allowances
|
|
0
|
|
(50)
|
|
0
|
|
(135)
|
|
(185)
|
|
(3)
|
|
(71)
|
|
0
|
|
(152)
|
|
(227)
|
Total on-balance
sheet, net
|
|
4,663
|
|
59,544
|
|
163
|
|
63,430
|
|
127,801
|
|
5,011
|
|
78,267
|
|
175
|
|
57,705
|
|
141,157
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Off-balance sheet
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contingent
liabilities, gross
|
|
0
|
|
9,646
|
|
988
|
|
8,183
|
|
18,818
|
|
0
|
|
7,467
|
|
997
|
|
8,900
|
|
17,364
|
Irrevocable
commitments, gross
|
|
219
|
|
6,902
|
|
119
|
|
7,801
|
|
15,041
|
|
231
|
|
7,468
|
|
206
|
|
7,953
|
|
15,858
|
Forward starting
reverse repurchase and securities borrowing transactions
|
|
|
|
25,273
|
|
|
|
0
|
|
25,273
|
|
|
|
22,390
|
|
|
|
0
|
|
22,390
|
Liabilities for
calls on shares and other equities
|
|
|
|
|
|
|
|
4
|
|
4
|
|
|
|
|
|
|
|
4
|
|
4
|
Total off-balance
sheet
|
|
219
|
|
41,821
|
|
1,107
|
|
15,988
|
|
59,135
|
|
231
|
|
37,325
|
|
1,203
|
|
16,857
|
|
55,616
|
1 Mainly includes cash and securities. 2 Includes
guarantees. 3 Includes prime brokerage margin lending receivables and
prime brokerage receivables relating to securities financing transactions.
4 Primarily consists of amounts due from subsidiaries and other Group
entities. 5 Consists of office and business premises, industrial premises
and other mortgages.
|
UBS AG standalone
financial statements (audited) 13
Note 12b
Credit-impaired financial instruments
|
|
31.12.22
|
|
31.12.21
|
USD m
|
|
Gross credit- impaired financial instruments
|
Allowances and
provisions
|
Estimated liquidation
proceeds of collateral
|
Net credit- impaired financial instruments
|
|
Gross credit- impaired financial instruments
|
Allowances and
provisions
|
Estimated liquidation
proceeds of collateral
|
Net credit- impaired financial instruments
|
Amounts due from
customers
|
|
318
|
105
|
213
|
0
|
|
395
|
147
|
184
|
63
|
Mortgage loans
|
|
185
|
0
|
184
|
0
|
|
118
|
4
|
114
|
0
|
Other assets
|
|
2
|
2
|
0
|
0
|
|
1
|
1
|
0
|
0
|
Guarantees and
loan commitments
|
|
73
|
0
|
40
|
33
|
|
14
|
0
|
14
|
0
|
Total
credit-impaired financial instruments1
|
|
577
|
107
|
437
|
33
|
|
528
|
153
|
312
|
63
|
1 Credit-impaired financial instruments are financial assets and
off-balance sheet positions subject to incurred credit losses, also referred
to as stage 3 positions.
|
|
|
31.12.22
|
|
31.12.21
|
CHF m
|
|
Gross credit- impaired financial instruments
|
Allowances and
provisions
|
Estimated liquidation
proceeds of collateral
|
Net credit- impaired financial instruments
|
|
Gross credit- impaired financial instruments
|
Allowances and
provisions
|
Estimated liquidation
proceeds of collateral
|
Net credit- impaired financial instruments
|
Amounts due from
customers
|
|
294
|
97
|
197
|
0
|
|
360
|
134
|
168
|
58
|
Mortgage loans
|
|
171
|
0
|
170
|
0
|
|
108
|
4
|
104
|
0
|
Other assets
|
|
2
|
2
|
0
|
0
|
|
1
|
1
|
0
|
0
|
Guarantees and
loan commitments
|
|
67
|
0
|
37
|
31
|
|
13
|
0
|
13
|
0
|
Total
credit-impaired financial instruments1
|
|
534
|
99
|
404
|
31
|
|
481
|
139
|
285
|
58
|
1 Credit-impaired financial instruments are financial assets and
off-balance sheet positions subject to incurred credit losses, also referred
to as stage 3 positions.
|
Note 13
Allowances and provisions
Allowances and provisions of USD 2,237m
(CHF 2,068m) as of 31 December 2022 included allowances and
provisions for credit losses of USD 286m (CHF 266m). Allowances and
provisions of USD 2,395m (CHF 2,184m) as of 31 December 2021 included
allowances and provisions for credit losses of USD 336m (CHF 307m).
The 2022 decrease in allowances and provisions for credit
losses of USD 49m (CHF 41m) included net credit loss releases of
USD 18m (CHF 17m) primarily related to credit-impaired positions, as
well as USD 31m (CHF 24m) for write-offs and other movements that did
not impact the income statement.
Net credit loss releases in 2022 included a net release of
USD 17m (CHF 16m) on credit-impaired positions, including a
release for a single airline-related counterparty of USD 28m (CHF 27m) in the
Investment Bank, and a net expense of USD 10m (CHF 10m) across a number of
defaulted positions.
Note 13a
Allowances for credit losses
USD m
|
Balance
as of
31.12.21
|
Increase
recognized
in the
income
statement
|
Release
recognized
in the
income
statement
|
Write-offs
|
Recoveries
and past
due interest
|
Reclassifications / other
|
Foreign
currency
translation
|
Balance
as of
31.12.22
|
Default risk
relating to on-balance sheet exposures
|
259
|
0
|
(18)
|
(22)
|
0
|
0
|
(8)
|
211
|
of which: incurred
credit losses
|
153
|
0
|
(17)
|
(22)
|
0
|
0
|
(8)
|
107
|
of which: expected
credit losses 1
|
106
|
0
|
(1)
|
0
|
0
|
0
|
0
|
104
|
Total allowances
for credit losses
|
259
|
0
|
(18)
|
(22)
|
0
|
0
|
(8)
|
211
|
1 Includes ECL
allowances where an approach other than IFRS ECL is applied of USD 0m as of
31 December 2022 (USD 4m as of 31 December 2021). Refer to Note 2 for more
information.
|
CHF m
|
Balance
as of
31.12.21
|
Increase
recognized
in the
income
statement
|
Release
recognized
in the
income
statement
|
Write-offs
|
Recoveries
and past
due interest
|
Reclassifications / other
|
Foreign
currency
translation
|
Balance
as of
31.12.22
|
Default risk
relating to on-balance sheet exposures
|
237
|
0
|
(17)
|
(21)
|
0
|
0
|
(4)
|
196
|
of which: incurred
credit losses
|
139
|
0
|
(16)
|
(21)
|
0
|
0
|
(4)
|
99
|
of which: expected
credit losses 1
|
98
|
0
|
(1)
|
0
|
0
|
0
|
1
|
97
|
Total allowances
for credit losses
|
237
|
0
|
(17)
|
(21)
|
0
|
0
|
(4)
|
196
|
1 Includes ECL
allowances where an approach other than IFRS ECL is applied of CHF 0m as of
31 December 2022 (CHF 4m as of 31 December 2021). Refer to Note 2 for more
information.
|
UBS AG standalone
financial statements (audited) 14
USD m
|
Balance
as of
31.12.21
|
Increase
recognized
in the
income
statement
|
Release
recognized
in the
income
statement
|
Provisions
used in
conformity
with
designated
purpose
|
Recoveries
|
Reclassifications
|
Foreign
currency translation / other2
|
Balance
as of
31.12.22
|
Default risk
related to off-balance sheet items and credit lines
|
77
|
0
|
0
|
0
|
0
|
0
|
(1)
|
76
|
of which: expected
credit losses
|
77
|
0
|
0
|
0
|
0
|
0
|
(1)
|
76
|
Litigation,
regulatory and similar matters
|
1,711
|
59
|
(5)
|
(35)
|
0
|
0
|
(86)
|
1,643
|
Restructuring
|
70
|
53
|
(12)
|
(58)
|
0
|
0
|
(2)
|
51
|
Real estate1
|
130
|
1
|
(5)
|
(15)
|
0
|
0
|
(2)
|
109
|
Employee benefits
|
25
|
7
|
(4)
|
0
|
0
|
0
|
(1)
|
27
|
Deferred taxes
|
71
|
21
|
0
|
0
|
0
|
0
|
0
|
92
|
Other
|
52
|
6
|
(27)
|
(2)
|
0
|
0
|
(1)
|
28
|
Total provisions
|
2,136
|
146
|
(52)
|
(111)
|
0
|
0
|
(93)
|
2,026
|
1 Includes provisions for onerous contracts of USD 51m
as of 31 December 2022 (31 December 2021: USD 67m) and
reinstatement cost provisions for leasehold improvements of USD 58m as
of 31 December 2022 (31 December 2021: USD 63m).
2 Other mainly includes changes related to unwind of discounting.
|
CHF m
|
Balance
as of
31.12.21
|
Increase
recognized
in the
income
statement
|
Release
recognized
in the
income
statement
|
Provisions
used in
conformity
with
designated
purpose
|
Recoveries
|
Reclassifications
|
Foreign
currency translation / other2
|
Balance
as of
31.12.22
|
Default risk
related to off-balance sheet items and credit lines
|
70
|
0
|
0
|
0
|
0
|
0
|
0
|
70
|
of which: expected
credit losses
|
70
|
0
|
0
|
0
|
0
|
0
|
0
|
70
|
Litigation,
regulatory and similar matters
|
1,560
|
55
|
(4)
|
(34)
|
0
|
0
|
(57)
|
1,518
|
Restructuring
|
64
|
50
|
(12)
|
(56)
|
0
|
0
|
0
|
47
|
Real estate1
|
119
|
1
|
(5)
|
(14)
|
0
|
0
|
0
|
101
|
Employee benefits
|
23
|
6
|
(4)
|
0
|
0
|
0
|
(1)
|
25
|
Deferred taxes
|
65
|
20
|
0
|
0
|
0
|
0
|
1
|
85
|
Other
|
47
|
5
|
(26)
|
(2)
|
0
|
0
|
1
|
26
|
Total provisions
|
1,947
|
137
|
(50)
|
(106)
|
0
|
0
|
(56)
|
1,872
|
1 Includes provisions for onerous contracts of CHF 47m
as of 31 December 2022 (31 December 2021: CHF 61m) and
reinstatement cost provisions for leasehold improvements of CHF 54m as
of 31 December 2022 (31 December 2021: CHF 58m).
2 Other mainly includes changes related to unwind of discounting.
|
UBS AG standalone
financial statements (audited) 15
Note 13c
Development of ECL allowances and provisions
USD m
|
Total
|
Stage 1
|
Stage 2
|
Stage 3
|
Balance as of 31
December 2021
|
(336)
|
(148)
|
(35)
|
(153)
|
Net movement from
new and derecognized transactions1
|
13
|
4
|
11
|
(2)
|
of which: Large
corporate clients
|
11
|
2
|
11
|
(2)
|
Remeasurements
with stage transfers2
|
(23)
|
13
|
(20)
|
(16)
|
of which: Large
corporate clients
|
(30)
|
14
|
(29)
|
(15)
|
Remeasurements
without stage transfers3
|
28
|
(4)
|
(3)
|
34
|
of which: Large
corporate clients
|
24
|
(5)
|
(2)
|
31
|
Model changes4
|
0
|
1
|
(1)
|
0
|
Total ECL
allowance movements with profit or loss impact
|
17
|
14
|
(13)
|
17
|
Movements without
profit or loss impact (write-off, FX and other)5
|
31
|
1
|
0
|
30
|
Balance as of 31
December 2022
|
(287)
|
(132)
|
(47)
|
(107)
|
1 Represents the increase and decrease in allowances and
provisions resulting from financial instruments (including guarantees and facilities)
that were newly originated, purchased or renewed and from the final
derecognition of loans or facilities on their maturity date or earlier. 2
Represents the remeasurement between 12-month and lifetime ECL due to stage
transfers. 3 Represents the change in allowances and provisions
related to changes in model inputs or assumptions, including changes in
forward-looking macroeconomic conditions, changes in the exposure profile, PD
and LGD changes, and unwinding of the time value. 4 Represents the change
in the allowances and provisions related to changes in models and
methodologies. 5 Represents the decrease in allowances and provisions
resulting from write-offs of the ECL allowance against the gross carrying
amount when all or part of a financial asset is deemed uncollectible or
forgiven and movements in foreign exchange rates.
|
CHF m
|
Total
|
Stage 1
|
Stage 2
|
Stage 3
|
Balance as of 31
December 2021
|
(307)
|
(136)
|
(32)
|
(139)
|
Net movement from
new and derecognized transactions1
|
12
|
4
|
11
|
(2)
|
of which: Large
corporate clients
|
10
|
2
|
11
|
(2)
|
Remeasurements
with stage transfers2
|
(21)
|
13
|
(19)
|
(15)
|
of which: Large
corporate clients
|
(28)
|
13
|
(28)
|
(14)
|
Remeasurements
without stage transfers3
|
27
|
(4)
|
(3)
|
33
|
of which: Large
corporate clients
|
22
|
(4)
|
(2)
|
29
|
Model changes4
|
0
|
0
|
(1)
|
0
|
Total ECL
allowance movements with profit or loss impact
|
17
|
13
|
(12)
|
16
|
Movements without
profit or loss impact (write-off, FX and other)5
|
24
|
(1)
|
0
|
25
|
Balance as of 31
December 2022
|
(266)
|
(123)
|
(44)
|
(99)
|
1 Represents the increase and decrease in allowances and
provisions resulting from financial instruments (including guarantees and
facilities) that were newly originated, purchased or renewed and from the
final derecognition of loans or facilities on their maturity date or
earlier. 2 Represents the remeasurement between 12-month and lifetime ECL
due to stage transfers. 3 Represents the change in allowances and
provisions related to changes in model inputs or assumptions, including
changes in forward-looking macroeconomic conditions, changes in the exposure
profile, PD and LGD changes, and unwinding of the time value. 4 Represents
the change in the allowances and provisions related to changes in models and
methodologies. 5 Represents the decrease in allowances and provisions
resulting from write-offs of the ECL allowance against the gross carrying
amount when all or part of a financial asset is deemed uncollectible or
forgiven and movements in foreign exchange rates.
|
UBS AG standalone
financial statements (audited) 16
Note 13c
Development of ECL allowances and provisions (continued)
USD m
|
Total
|
Stage 1
|
Stage 2
|
Stage 3
|
Balance as of 31
December 2020
|
(556)
|
(193)
|
(65)
|
(298)
|
Net movement from
new and derecognized transactions1
|
15
|
6
|
9
|
0
|
of which: Large
corporate clients
|
1
|
(8)
|
9
|
0
|
Remeasurements
with stage transfers2
|
(2)
|
1
|
7
|
(10)
|
of which: Large
corporate clients
|
(1)
|
1
|
7
|
(8)
|
Remeasurements
without stage transfers3
|
33
|
14
|
4
|
15
|
of which: Large
corporate clients
|
9
|
(5)
|
3
|
10
|
Model changes4
|
32
|
23
|
9
|
0
|
Total ECL
allowance movements with profit or loss impact
|
78
|
44
|
29
|
6
|
Movements without
profit or loss impact (write-off, FX and other)5
|
142
|
1
|
0
|
140
|
Balance as of 31
December 2021
|
(336)
|
(148)
|
(35)
|
(153)
|
1 Represents the increase and decrease in allowances and
provisions resulting from financial instruments (including guarantees and
facilities) that were newly originated, purchased or renewed and from the
final derecognition of loans or facilities on their maturity date or
earlier. 2 Represents the remeasurement between 12-month and lifetime ECL
due to stage transfers. 3 Represents the change in allowances and
provisions related to changes in model inputs or assumptions, including changes
in forward-looking macroeconomic conditions, changes in the exposure profile,
PD and LGD changes, and unwinding of the time value. 4 Represents the
change in the allowances and provisions related to changes in models and
methodologies. 5 Represents the decrease in allowances and provisions
resulting from write-offs of the ECL allowance against the gross carrying
amount when all or part of a financial asset is deemed uncollectible or
forgiven and movements in foreign exchange rates.
|
CHF m
|
Total
|
Stage 1
|
Stage 2
|
Stage 3
|
Balance as of 31
December 2020
|
(492)
|
(172)
|
(57)
|
(264)
|
Net movement from
new and derecognized transactions1
|
14
|
5
|
8
|
0
|
of which: Large
corporate clients
|
0
|
(8)
|
8
|
0
|
Remeasurements
with stage transfers2
|
(2)
|
1
|
7
|
(9)
|
of which: Large
corporate clients
|
(1)
|
1
|
7
|
(8)
|
Remeasurements
without stage transfers3
|
31
|
13
|
3
|
14
|
of which: Large
corporate clients
|
8
|
(4)
|
3
|
10
|
Model changes4
|
29
|
21
|
9
|
0
|
Total ECL
allowance movements with profit or loss impact
|
72
|
41
|
27
|
5
|
Movements without
profit or loss impact (write-off, FX and other)5
|
113
|
(6)
|
(2)
|
120
|
Balance as of 31
December 2021
|
(307)
|
(136)
|
(32)
|
(139)
|
1 Represents the increase and decrease in allowances and
provisions resulting from financial instruments (including guarantees and
facilities) that were newly originated, purchased or renewed and from the
final derecognition of loans or facilities on their maturity date or
earlier. 2 Represents the remeasurement between 12-month and lifetime ECL
due to stage transfers. 3 Represents the change in allowances and
provisions related to changes in model inputs or assumptions, including
changes in forward-looking macroeconomic conditions, changes in the exposure
profile, PD and LGD changes, and unwinding of the time value. 4 Represents
the change in the allowances and provisions related to changes in models and
methodologies. 5 Represents the decrease in allowances and provisions
resulting from write-offs of the ECL allowance against the gross carrying
amount when all or part of a financial asset is deemed uncollectible or
forgiven and movements in foreign exchange rates.
|
UBS AG standalone
financial statements (audited) 17
Note 13d
Balance sheet and off-balance sheet positions
subject to ECL
The tables below provide ECL exposure and allowance
and provision information about financial instruments and certain non-financial
instruments that are subject to ECL.
USD m
|
|
31.12.22
|
|
|
Carrying amount1
|
|
ECL allowances
|
Financial
instruments measured at amortized cost
|
|
Total
|
Stage 1
|
Stage 2
|
Stage 3
|
|
Total
|
Stage 1
|
Stage 2
|
Stage 3
|
Cash and balances
at central banks
|
|
48,344
|
48,344
|
0
|
0
|
|
0
|
0
|
0
|
0
|
Due from banks
|
|
31,450
|
31,450
|
0
|
0
|
|
(5)
|
(5)
|
0
|
0
|
Receivables from
securities financing transactions
|
|
58,141
|
58,141
|
0
|
0
|
|
(2)
|
(2)
|
0
|
0
|
Due from customers2
|
|
105,552
|
103,876
|
1,463
|
213
|
|
(174)
|
(59)
|
(9)
|
(105)
|
Funding provided
to significant regulated subsidiaries eligible as total loss-absorbing
capacity
|
|
27,678
|
27,678
|
0
|
0
|
|
(26)
|
(26)
|
0
|
0
|
Mortgage loans
|
|
5,039
|
4,837
|
17
|
184
|
|
0
|
0
|
0
|
0
|
Accrued income and
prepaid expenses
|
|
1,872
|
1,863
|
9
|
0
|
|
0
|
0
|
0
|
0
|
Other assets3
|
|
939
|
939
|
0
|
0
|
|
(3)
|
(1)
|
0
|
(2)
|
Total on-balance
sheet financial assets within the scope of ECL
|
|
279,015
|
277,128
|
1,490
|
397
|
|
(211)
|
(94)
|
(9)
|
(107)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total exposure
|
|
ECL provisions
|
Off-balance
sheet (within the scope of ECL)
|
|
Total
|
Stage 1
|
Stage 2
|
Stage 3
|
|
Total
|
Stage 1
|
Stage 2
|
Stage 3
|
Contingent
liabilities, gross
|
|
20,359
|
19,260
|
1,091
|
8
|
|
(3)
|
(2)
|
(1)
|
0
|
Irrevocable
commitments, gross
|
|
16,272
|
14,474
|
1,734
|
64
|
|
(72)
|
(35)
|
(37)
|
0
|
Forward starting
transactions (securities financing transactions)4
|
|
2,810
|
2,810
|
0
|
0
|
|
0
|
0
|
0
|
0
|
Credit lines
|
|
11,592
|
11,256
|
335
|
0
|
|
(1)
|
0
|
0
|
0
|
Irrevocable
committed prolongation of existing loans
|
|
147
|
147
|
0
|
0
|
|
0
|
0
|
0
|
0
|
Total off-balance
sheet financial instruments and credit lines within the scope of ECL
|
|
51,180
|
47,947
|
3,160
|
73
|
|
(76)
|
(38)
|
(38)
|
0
|
Total allowances
and provisions
|
|
|
|
|
|
|
(287)
|
(132)
|
(47)
|
(107)
|
1 The carrying amount of financial assets measured at amortized
cost represents the total gross exposure net of the respective ECL
allowances. 2 Includes USD 0m ECL allowances where an approach other than
“IFRS ECL” is applied. Refer to Note 2 for more information. 3
Includes components of other receivables due from UBS Group AG and
subsidiaries in the UBS Group and other assets within the scope of ECL.
Refer to Note 17a for more information. 4 Includes forward starting
reverse repurchase agreements within the scope of ECL.
|
CHF m
|
|
31.12.22
|
|
|
Carrying amount1
|
|
ECL allowances
|
Financial
instruments measured at amortized cost
|
|
Total
|
Stage 1
|
Stage 2
|
Stage 3
|
|
Total
|
Stage 1
|
Stage 2
|
Stage 3
|
Cash and balances
at central banks
|
|
44,684
|
44,684
|
0
|
0
|
|
0
|
0
|
0
|
0
|
Due from banks
|
|
29,069
|
29,069
|
0
|
0
|
|
(5)
|
(5)
|
0
|
0
|
Receivables from
securities financing transactions
|
|
53,739
|
53,739
|
0
|
0
|
|
(2)
|
(2)
|
0
|
0
|
Due from customers2
|
|
97,561
|
96,011
|
1,353
|
197
|
|
(161)
|
(55)
|
(9)
|
(97)
|
Funding provided
to significant regulated subsidiaries eligible as total loss-absorbing
capacity
|
|
25,582
|
25,582
|
0
|
0
|
|
(24)
|
(24)
|
0
|
0
|
Mortgage loans
|
|
4,657
|
4,471
|
16
|
170
|
|
0
|
0
|
0
|
0
|
Accrued income and
prepaid expenses
|
|
1,730
|
1,722
|
8
|
0
|
|
0
|
0
|
0
|
0
|
Other assets3
|
|
867
|
867
|
0
|
0
|
|
(3)
|
(1)
|
0
|
(2)
|
Total on-balance
sheet financial assets within the scope of ECL
|
|
257,890
|
256,146
|
1,377
|
367
|
|
(196)
|
(88)
|
(9)
|
(99)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total exposure
|
|
ECL provisions
|
Off-balance
sheet (within the scope of ECL)
|
|
Total
|
Stage 1
|
Stage 2
|
Stage 3
|
|
Total
|
Stage 1
|
Stage 2
|
Stage 3
|
Contingent
liabilities, gross
|
|
18,818
|
17,802
|
1,008
|
8
|
|
(3)
|
(2)
|
(1)
|
0
|
Irrevocable
commitments, gross
|
|
15,041
|
13,378
|
1,603
|
60
|
|
(66)
|
(32)
|
(34)
|
0
|
Forward starting
transactions (securities financing transactions)4
|
|
2,597
|
2,597
|
0
|
0
|
|
0
|
0
|
0
|
0
|
Credit lines
|
|
10,714
|
10,404
|
310
|
0
|
|
(1)
|
(1)
|
0
|
0
|
Irrevocable
committed prolongation of existing loans
|
|
135
|
135
|
0
|
0
|
|
0
|
0
|
0
|
0
|
Total off-balance
sheet financial instruments and credit lines within the scope of ECL
|
|
47,305
|
44,317
|
2,921
|
67
|
|
(70)
|
(35)
|
(35)
|
0
|
Total allowances
and provisions
|
|
|
|
|
|
|
(266)
|
(123)
|
(44)
|
(99)
|
1 The carrying amount of financial assets measured at amortized
cost represents the total gross exposure net of the respective ECL
allowances. 2 Includes CHF 0m ECL allowances where an approach other
than “IFRS ECL” is applied. Refer to Note 2 for more information.
3 Includes components of other receivables due from UBS Group AG
and subsidiaries in the UBS Group and other assets within the scope of
ECL. Refer to Note 17a for more information. 4 Includes forward
starting reverse repurchase agreements within the scope of ECL.
|
UBS AG standalone
financial statements (audited) 18
Note 13d
Balance sheet and off-balance sheet positions
subject to ECL (continued)
USD m
|
|
31.12.21
|
|
|
Carrying amount1
|
|
ECL allowances
|
Financial
instruments measured at amortized cost
|
|
Total
|
Stage 1
|
Stage 2
|
Stage 3
|
|
Total
|
Stage 1
|
Stage 2
|
Stage 3
|
Cash and balances
at central banks
|
|
53,760
|
53,760
|
0
|
0
|
|
0
|
0
|
0
|
0
|
Due from banks
|
|
33,330
|
33,330
|
0
|
0
|
|
(5)
|
(5)
|
0
|
0
|
Receivables from
securities financing transactions
|
|
56,336
|
56,336
|
0
|
0
|
|
(2)
|
(2)
|
0
|
0
|
Due from customers2
|
|
121,812
|
119,892
|
1,672
|
247
|
|
(214)
|
(56)
|
(10)
|
(147)
|
Funding provided
to significant regulated subsidiaries eligible as total loss-absorbing
capacity
|
|
27,530
|
27,530
|
0
|
0
|
|
(32)
|
(32)
|
0
|
0
|
Mortgage loans
|
|
5,492
|
5,379
|
0
|
114
|
|
(4)
|
0
|
0
|
(4)
|
Accrued income and
prepaid expenses
|
|
1,213
|
1,212
|
2
|
0
|
|
0
|
0
|
0
|
0
|
Other assets3
|
|
912
|
912
|
0
|
0
|
|
(2)
|
(1)
|
0
|
(1)
|
Total on-balance
sheet financial assets within the scope of ECL
|
|
300,386
|
298,351
|
1,674
|
361
|
|
(259)
|
(96)
|
(10)
|
(153)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total exposure
|
|
ECL provisions
|
Off-balance sheet
(within the scope of ECL)
|
|
Total
|
Stage 1
|
Stage 2
|
Stage 3
|
|
Total
|
Stage 1
|
Stage 2
|
Stage 3
|
Contingent
liabilities, gross
|
|
19,046
|
18,860
|
176
|
10
|
|
(4)
|
(3)
|
(1)
|
0
|
Irrevocable
commitments, gross
|
|
17,394
|
15,967
|
1,423
|
4
|
|
(72)
|
(49)
|
(24)
|
0
|
Forward starting
transactions (securities financing transactions)4
|
|
1,097
|
1,097
|
0
|
0
|
|
0
|
0
|
0
|
0
|
Credit lines
|
|
8,388
|
7,966
|
422
|
0
|
|
(1)
|
(1)
|
(1)
|
0
|
Irrevocable
committed prolongation of existing loans
|
|
736
|
736
|
0
|
0
|
|
0
|
0
|
0
|
0
|
Total off-balance
sheet financial instruments and credit lines within the scope of ECL
|
|
46,662
|
44,627
|
2,021
|
14
|
|
(77)
|
(52)
|
(25)
|
0
|
Total allowances
and provisions
|
|
|
|
|
|
|
(336)
|
(148)
|
(35)
|
(153)
|
1 The carrying amount of financial assets measured at amortized
cost represents the total gross exposure net of the respective ECL
allowances. 2 Includes USD 4m ECL allowances where an approach other than
“IFRS ECL” is applied. Refer to Note 2 for more information. 3 Includes
components of other receivables due from UBS Group AG and subsidiaries in the
UBS Group and other assets within the scope of ECL. Refer to Note 17a for
more information. 4 Includes forward starting reverse repurchase agreements
within the scope of ECL.
|
CHF m
|
|
31.12.21
|
|
|
Carrying amount1
|
|
ECL allowances
|
Financial
instruments measured at amortized cost
|
|
Total
|
Stage 1
|
Stage 2
|
Stage 3
|
|
Total
|
Stage 1
|
Stage 2
|
Stage 3
|
Cash and balances
at central banks
|
|
49,012
|
49,012
|
0
|
0
|
|
0
|
0
|
0
|
0
|
Due from banks
|
|
30,386
|
30,386
|
0
|
0
|
|
(5)
|
(5)
|
0
|
0
|
Receivables from
securities financing transactions
|
|
51,360
|
51,360
|
0
|
0
|
|
(2)
|
(2)
|
0
|
0
|
Due from customers2
|
|
111,052
|
109,302
|
1,524
|
225
|
|
(195)
|
(51)
|
(9)
|
(134)
|
Funding provided
to significant regulated subsidiaries eligible as total loss-absorbing
capacity
|
|
25,098
|
25,098
|
0
|
0
|
|
(29)
|
(29)
|
0
|
0
|
Mortgage loans
|
|
5,007
|
4,904
|
0
|
104
|
|
(4)
|
0
|
0
|
(4)
|
Accrued income and
prepaid expenses
|
|
1,106
|
1,105
|
1
|
0
|
|
0
|
0
|
0
|
0
|
Other assets3
|
|
832
|
832
|
0
|
0
|
|
(2)
|
(1)
|
0
|
(1)
|
Total on-balance
sheet financial assets within the scope of ECL
|
|
273,853
|
271,998
|
1,526
|
329
|
|
(237)
|
(89)
|
(9)
|
(139)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total exposure
|
|
ECL provisions
|
Off-balance sheet
(within the scope of ECL)
|
|
Total
|
Stage 1
|
Stage 2
|
Stage 3
|
|
Total
|
Stage 1
|
Stage 2
|
Stage 3
|
Contingent
liabilities, gross
|
|
17,364
|
17,194
|
160
|
9
|
|
(3)
|
(2)
|
(1)
|
0
|
Irrevocable
commitments, gross
|
|
15,858
|
14,557
|
1,298
|
4
|
|
(65)
|
(44)
|
(21)
|
0
|
Forward starting
transactions (securities financing transactions)4
|
|
1,000
|
1,000
|
0
|
0
|
|
0
|
0
|
0
|
0
|
Credit lines
|
|
7,647
|
7,263
|
384
|
0
|
|
(2)
|
(1)
|
(1)
|
0
|
Irrevocable
committed prolongation of existing loans
|
|
671
|
671
|
0
|
0
|
|
0
|
0
|
0
|
0
|
Total off-balance
sheet financial instruments and credit lines within the scope of ECL
|
|
42,540
|
40,685
|
1,842
|
13
|
|
(70)
|
(47)
|
(23)
|
0
|
Total allowances
and provisions
|
|
|
|
|
|
|
(307)
|
(136)
|
(32)
|
(139)
|
1 The carrying amount of financial assets measured at amortized
cost represents the total gross exposure net of the respective ECL
allowances. 2 Includes CHF 4m ECL allowances where an approach other
than “IFRS ECL” is applied. Refer to Note 2 for more information.
3 Includes components of other receivables due from UBS Group AG
and subsidiaries in the UBS Group and other assets within the scope of
ECL. Refer to Note 17a for more information. 4 Includes forward
starting reverse repurchase agreements within the scope of ECL.
|
UBS AG standalone
financial statements (audited) 19
Note 13e Financial assets subject to credit risk by rating category
The table below shows the credit quality and the
maximum exposure to credit risk based on the Group’s internal credit rating
system and year-end stage classification.
Financial assets subject to credit risk by rating category
|
USD m
|
|
31.12.22
|
Rating category
|
|
0–1
|
2–3
|
4–5
|
6–8
|
9–13
|
Credit-impaired (defaulted)
|
Total gross carrying amount
|
ECL allowances
|
Net carrying amount (maximum exposure to credit risk)
|
Financial
instruments measured at amortized cost
|
|
|
|
|
|
|
|
|
|
|
Cash and balances
at central banks
|
|
48,227
|
117
|
0
|
0
|
0
|
0
|
48,344
|
0
|
48,344
|
of which: stage 1
|
|
48,227
|
117
|
0
|
0
|
0
|
0
|
48,344
|
0
|
48,344
|
Due from banks
|
|
867
|
29,915
|
640
|
0
|
33
|
0
|
31,455
|
(5)
|
31,450
|
of which: stage 1
|
|
867
|
29,915
|
640
|
0
|
33
|
0
|
31,455
|
(5)
|
31,450
|
Receivables from
securities financing transactions
|
|
14,930
|
8,597
|
7,564
|
26,332
|
721
|
0
|
58,143
|
(2)
|
58,141
|
of which: stage 1
|
|
14,930
|
8,597
|
7,564
|
26,332
|
721
|
0
|
58,143
|
(2)
|
58,141
|
Due from customers
|
|
4,619
|
38,780
|
8,602
|
50,987
|
2,420
|
318
|
105,726
|
(174)
|
105,552
|
of which: stage 1
|
|
4,619
|
38,780
|
8,295
|
50,433
|
1,809
|
0
|
103,936
|
(59)
|
103,876
|
of which: stage 2
|
|
0
|
0
|
307
|
555
|
611
|
0
|
1,473
|
(9)
|
1,463
|
of which: stage 3
|
|
0
|
0
|
0
|
0
|
0
|
318
|
318
|
(105)
|
213
|
Funding provided
to significant regulated subsidiaries eligible as total loss-absorbing
capacity
|
|
0
|
27,704
|
0
|
0
|
0
|
0
|
27,704
|
(26)
|
27,678
|
of which: stage 1
|
|
0
|
27,704
|
0
|
0
|
0
|
0
|
27,704
|
(26)
|
27,678
|
Mortgage loans
|
|
0
|
1
|
302
|
4,063
|
488
|
185
|
5,039
|
0
|
5,039
|
of which: stage 1
|
|
0
|
1
|
302
|
4,045
|
488
|
0
|
4,837
|
0
|
4,837
|
of which: stage 2
|
|
0
|
0
|
0
|
17
|
0
|
0
|
17
|
0
|
17
|
of which: stage 3
|
|
0
|
0
|
0
|
0
|
0
|
185
|
185
|
0
|
184
|
Accrued income and
prepaid expenses
|
|
130
|
671
|
352
|
687
|
33
|
0
|
1,872
|
0
|
1,872
|
of which: stage 1
|
|
130
|
671
|
351
|
681
|
31
|
0
|
1,863
|
0
|
1,863
|
of which: stage 2
|
|
0
|
0
|
0
|
6
|
2
|
0
|
9
|
0
|
9
|
Other assets
|
|
0
|
155
|
4
|
776
|
5
|
2
|
942
|
(3)
|
939
|
of which: stage 1
|
|
0
|
155
|
4
|
776
|
5
|
0
|
940
|
(1)
|
939
|
of which: stage 3
|
|
0
|
0
|
0
|
0
|
0
|
2
|
2
|
(2)
|
0
|
Total in scope of
ECL assets / ECL amounts by stages
|
|
68,772
|
105,939
|
17,464
|
82,845
|
3,701
|
504
|
279,225
|
(211)
|
279,015
|
Off-balance sheet positions and credit lines subject to expected
credit loss by rating category
|
USD m
|
|
31.12.22
|
Rating category
|
|
0–1
|
2–3
|
4–5
|
6–8
|
9–13
|
Credit-impaired
(defaulted)
|
Total off-balance sheet exposure
(maximum exposure to credit risk)
|
ECL provisions
|
Off-balance sheet
(within the scope of ECL)
|
|
|
|
|
|
|
|
|
|
Contingent
liabilities, gross
|
|
7,157
|
9,102
|
2,464
|
1,273
|
356
|
8
|
20,359
|
(3)
|
of which: stage 1
|
|
7,157
|
9,072
|
1,555
|
1,247
|
229
|
0
|
19,260
|
(2)
|
of which: stage 2
|
|
0
|
30
|
909
|
25
|
127
|
0
|
1,091
|
(1)
|
of which: stage 3
|
|
0
|
0
|
0
|
0
|
0
|
8
|
8
|
0
|
Irrevocable
commitments, gross
|
|
1,239
|
5,068
|
3,146
|
1,895
|
4,860
|
64
|
16,272
|
(72)
|
of which: stage 1
|
|
1,239
|
4,948
|
3,030
|
1,771
|
3,485
|
0
|
14,474
|
(35)
|
of which: stage 2
|
|
0
|
120
|
115
|
124
|
1,375
|
0
|
1,734
|
(37)
|
of which: stage 3
|
|
0
|
0
|
0
|
0
|
0
|
64
|
64
|
0
|
Forward starting
transactions (securities financing transactions)
|
|
1,790
|
2
|
11
|
1,007
|
0
|
0
|
2,810
|
0
|
of which: stage 1
|
|
1,790
|
2
|
11
|
1,007
|
0
|
0
|
2,810
|
0
|
Credit lines
|
|
0
|
3,868
|
687
|
5,851
|
1,186
|
0
|
11,592
|
(1)
|
of which: stage 1
|
|
0
|
3,825
|
616
|
5,700
|
1,115
|
0
|
11,256
|
0
|
of which: stage 2
|
|
0
|
43
|
71
|
150
|
71
|
0
|
335
|
0
|
Irrevocable
committed prolongation of existing loans
|
|
0
|
147
|
0
|
0
|
0
|
0
|
147
|
0
|
of which: stage 1
|
|
0
|
147
|
0
|
0
|
0
|
0
|
147
|
0
|
Total off-balance
sheet financial instruments and credit lines
|
|
10,186
|
18,186
|
6,307
|
10,026
|
6,402
|
73
|
51,180
|
(76)
|
UBS AG standalone
financial statements (audited) 20
Note 13e
Financial assets subject to credit risk by
rating category (continued)
Financial assets subject to credit risk by rating category
|
CHF m
|
|
31.12.22
|
Rating category
|
|
0–1
|
2–3
|
4–5
|
6–8
|
9–13
|
Credit-impaired (defaulted)
|
Total gross carrying amount
|
ECL allowances
|
Net carrying amount (maximum exposure to credit risk)
|
Financial
instruments measured at amortized cost
|
|
|
|
|
|
|
|
|
|
|
Cash and balances
at central banks
|
|
44,576
|
108
|
0
|
0
|
0
|
0
|
44,684
|
0
|
44,684
|
of which: stage 1
|
|
44,576
|
108
|
0
|
0
|
0
|
0
|
44,684
|
0
|
44,684
|
Due from banks
|
|
801
|
27,650
|
591
|
0
|
30
|
0
|
29,073
|
(5)
|
29,069
|
of which: stage 1
|
|
801
|
27,650
|
591
|
0
|
30
|
0
|
29,073
|
(5)
|
29,069
|
Receivables from
securities financing transactions
|
|
13,799
|
7,946
|
6,991
|
24,338
|
667
|
0
|
53,741
|
(2)
|
53,739
|
of which: stage 1
|
|
13,799
|
7,946
|
6,991
|
24,338
|
667
|
0
|
53,741
|
(2)
|
53,739
|
Due from customers
|
|
4,269
|
35,844
|
7,950
|
47,127
|
2,237
|
294
|
97,722
|
(161)
|
97,561
|
of which: stage 1
|
|
4,269
|
35,844
|
7,667
|
46,614
|
1,672
|
0
|
96,067
|
(55)
|
96,011
|
of which: stage 2
|
|
0
|
0
|
283
|
513
|
565
|
0
|
1,361
|
(9)
|
1,353
|
of which: stage 3
|
|
0
|
0
|
0
|
0
|
0
|
294
|
294
|
(97)
|
197
|
Funding provided
to significant regulated subsidiaries eligible as total loss-absorbing
capacity
|
|
0
|
25,607
|
0
|
0
|
0
|
0
|
25,607
|
(24)
|
25,582
|
of which: stage 1
|
|
0
|
25,607
|
0
|
0
|
0
|
0
|
25,607
|
(24)
|
25,582
|
Mortgage loans
|
|
0
|
1
|
279
|
3,755
|
451
|
171
|
4,657
|
0
|
4,657
|
of which: stage 1
|
|
0
|
1
|
279
|
3,739
|
451
|
0
|
4,471
|
0
|
4,471
|
of which: stage 2
|
|
0
|
0
|
0
|
16
|
0
|
0
|
16
|
0
|
16
|
of which: stage 3
|
|
0
|
0
|
0
|
0
|
0
|
171
|
171
|
0
|
170
|
Accrued income and
prepaid expenses
|
|
120
|
620
|
325
|
635
|
31
|
0
|
1,730
|
0
|
1,730
|
of which: stage 1
|
|
120
|
620
|
325
|
629
|
29
|
0
|
1,722
|
0
|
1,722
|
of which: stage 2
|
|
0
|
0
|
0
|
6
|
2
|
0
|
8
|
0
|
8
|
Other assets
|
|
0
|
143
|
4
|
717
|
4
|
1
|
870
|
(3)
|
867
|
of which: stage 1
|
|
0
|
143
|
4
|
717
|
4
|
0
|
869
|
(1)
|
867
|
of which: stage 3
|
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
(2)
|
0
|
Total in scope of
ECL assets / ECL amounts by stages
|
|
63,565
|
97,918
|
16,141
|
76,573
|
3,421
|
466
|
258,085
|
(196)
|
257,890
|
Off-balance sheet positions and credit lines subject to expected
credit loss by rating category
|
CHF m
|
|
31.12.22
|
Rating category
|
|
0–1
|
2–3
|
4–5
|
6–8
|
9–13
|
Credit-impaired
(defaulted)
|
Total off-balance sheet exposure
(maximum exposure to credit risk)
|
ECL provisions
|
Off-balance sheet
(within the scope of ECL)
|
|
|
|
|
|
|
|
|
|
Contingent
liabilities, gross
|
|
6,615
|
8,413
|
2,277
|
1,176
|
329
|
8
|
18,818
|
(3)
|
of which: stage 1
|
|
6,615
|
8,385
|
1,438
|
1,153
|
211
|
0
|
17,802
|
(2)
|
of which: stage 2
|
|
0
|
27
|
840
|
23
|
118
|
0
|
1,008
|
(1)
|
of which: stage 3
|
|
0
|
0
|
0
|
0
|
0
|
8
|
8
|
0
|
Irrevocable
commitments, gross
|
|
1,145
|
4,684
|
2,907
|
1,752
|
4,492
|
60
|
15,041
|
(66)
|
of which: stage 1
|
|
1,145
|
4,574
|
2,801
|
1,637
|
3,221
|
0
|
13,378
|
(32)
|
of which: stage 2
|
|
0
|
111
|
107
|
115
|
1,271
|
0
|
1,603
|
(34)
|
of which: stage 3
|
|
0
|
0
|
0
|
0
|
0
|
60
|
60
|
0
|
Forward starting
transactions (securities financing transactions)
|
|
1,655
|
2
|
10
|
931
|
0
|
0
|
2,597
|
0
|
of which: stage 1
|
|
1,655
|
2
|
10
|
931
|
0
|
0
|
2,597
|
0
|
Credit lines
|
|
0
|
3,575
|
635
|
5,408
|
1,096
|
0
|
10,714
|
(1)
|
of which: stage 1
|
|
0
|
3,536
|
569
|
5,269
|
1,030
|
0
|
10,404
|
(1)
|
of which: stage 2
|
|
0
|
40
|
66
|
139
|
66
|
0
|
310
|
0
|
Irrevocable
committed prolongation of existing loans
|
|
0
|
135
|
0
|
0
|
0
|
0
|
135
|
0
|
of which: stage 1
|
|
0
|
135
|
0
|
0
|
0
|
0
|
135
|
0
|
Total off-balance
sheet financial instruments and credit lines
|
|
9,415
|
16,810
|
5,829
|
9,267
|
5,917
|
67
|
47,305
|
(70)
|
› Refer to Note 9 and Note 19 to the UBS AG consolidated
financial statements in the UBS Group AG and UBS AG Annual Report 2022 for more
information about ECL in accordance with IFRS
UBS AG standalone
financial statements (audited) 21
Note 13e
Financial assets subject to credit risk by
rating category (continued)
Financial assets subject to credit risk by rating category
|
USD m
|
|
31.12.21
|
Rating category
|
|
0–1
|
2–3
|
4–5
|
6–8
|
9–13
|
Credit-impaired (defaulted)
|
Total gross carrying amount
|
ECL allowances
|
Net carrying amount (maximum exposure to credit risk)
|
Financial
instruments measured at amortized cost
|
|
|
|
|
|
|
|
|
|
|
Cash and balances
at central banks
|
|
53,680
|
80
|
0
|
0
|
0
|
0
|
53,760
|
0
|
53,760
|
of which: stage 1
|
|
53,680
|
80
|
0
|
0
|
0
|
0
|
53,760
|
0
|
53,760
|
Due from banks
|
|
466
|
32,410
|
454
|
0
|
4
|
0
|
33,335
|
(5)
|
33,330
|
of which: stage 1
|
|
466
|
32,410
|
454
|
0
|
4
|
0
|
33,335
|
(5)
|
33,330
|
Receivables from
securities financing transactions
|
|
13,983
|
8,793
|
8,256
|
23,871
|
1,435
|
0
|
56,338
|
(2)
|
56,336
|
of which: stage 1
|
|
13,983
|
8,793
|
8,256
|
23,871
|
1,435
|
0
|
56,338
|
(2)
|
56,336
|
Due from customers
|
|
3,116
|
34,793
|
14,591
|
66,766
|
2,365
|
395
|
122,025
|
(214)
|
121,812
|
of which: stage 1
|
|
3,116
|
34,790
|
14,236
|
66,007
|
1,800
|
0
|
119,948
|
(56)
|
119,892
|
of which: stage 2
|
|
0
|
3
|
355
|
759
|
566
|
0
|
1,682
|
(10)
|
1,672
|
of which: stage 3
|
|
0
|
0
|
0
|
0
|
0
|
395
|
395
|
(147)
|
247
|
Funding provided
to significant regulated subsidiaries eligible as total loss-absorbing
capacity
|
|
0
|
27,561
|
0
|
0
|
0
|
0
|
27,561
|
(32)
|
27,530
|
of which: stage 1
|
|
0
|
27,561
|
0
|
0
|
0
|
0
|
27,561
|
(32)
|
27,530
|
Mortgage loans
|
|
0
|
2
|
457
|
4,919
|
1
|
118
|
5,496
|
(4)
|
5,492
|
of which: stage 1
|
|
0
|
1
|
457
|
4,919
|
1
|
0
|
5,379
|
0
|
5,379
|
of which: stage 3
|
|
0
|
0
|
0
|
0
|
0
|
118
|
118
|
(4)
|
114
|
Accrued income and
prepaid expenses
|
|
47
|
225
|
327
|
582
|
33
|
0
|
1,213
|
0
|
1,213
|
of which: stage 1
|
|
47
|
225
|
327
|
581
|
32
|
0
|
1,212
|
0
|
1,212
|
of which: stage 2
|
|
0
|
0
|
0
|
1
|
1
|
0
|
2
|
0
|
2
|
Other assets
|
|
0
|
100
|
2
|
810
|
3
|
1
|
915
|
(2)
|
912
|
of which: stage 1
|
|
0
|
100
|
2
|
810
|
3
|
0
|
914
|
(1)
|
912
|
of which: stage 3
|
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
(1)
|
0
|
Total in scope of
ECL assets / ECL amounts by stages
|
|
71,293
|
103,963
|
24,086
|
96,948
|
3,841
|
514
|
300,644
|
(259)
|
300,386
|
Off-balance sheet positions and credit lines subject to expected
credit loss by rating category
|
USD m
|
|
31.12.21
|
Rating category
|
|
0–1
|
2–3
|
4–5
|
6–8
|
9–13
|
Credit-impaired
(defaulted)
|
Total off- balance sheet exposure
(maximum exposure to credit risk)
|
ECL provisions
|
Off-balance sheet
(within the scope of ECL)
|
|
|
|
|
|
|
|
|
|
Contingent
liabilities, gross
|
|
4,385
|
10,960
|
1,782
|
1,498
|
411
|
10
|
19,046
|
(4)
|
of which: stage 1
|
|
4,385
|
10,937
|
1,729
|
1,495
|
315
|
0
|
18,860
|
(3)
|
of which: stage 2
|
|
0
|
24
|
52
|
3
|
97
|
0
|
176
|
(1)
|
of which: stage 3
|
|
0
|
0
|
0
|
0
|
0
|
10
|
10
|
0
|
Irrevocable
commitments, gross
|
|
1,778
|
5,058
|
3,316
|
2,082
|
5,156
|
4
|
17,394
|
(72)
|
of which: stage 1
|
|
1,778
|
4,792
|
3,107
|
1,758
|
4,532
|
0
|
15,967
|
(49)
|
of which: stage 2
|
|
0
|
266
|
209
|
324
|
624
|
0
|
1,423
|
(24)
|
of which: stage 3
|
|
0
|
0
|
0
|
0
|
0
|
4
|
4
|
0
|
Forward starting
transactions (securities financing transactions)
|
|
0
|
0
|
0
|
1,097
|
0
|
0
|
1,097
|
0
|
of which: stage 1
|
|
0
|
0
|
0
|
1,097
|
0
|
0
|
1,097
|
0
|
Credit lines
|
|
6
|
3,314
|
135
|
3,771
|
1,161
|
0
|
8,388
|
(1)
|
of which: stage 1
|
|
6
|
3,266
|
8
|
3,567
|
1,119
|
0
|
7,966
|
(1)
|
of which: stage 2
|
|
0
|
48
|
127
|
204
|
42
|
0
|
422
|
(1)
|
Irrevocable
committed prolongation of existing loans
|
|
0
|
736
|
0
|
0
|
0
|
0
|
736
|
0
|
of which: stage 1
|
|
0
|
736
|
0
|
0
|
0
|
0
|
736
|
0
|
Total off-balance
sheet financial instruments and credit lines
|
|
6,168
|
20,069
|
5,233
|
8,448
|
6,729
|
14
|
46,662
|
(77)
|
UBS AG standalone
financial statements (audited) 22
Note 13e
Financial assets subject to credit risk by
rating category (continued)
Financial assets subject to credit risk by rating category
|
CHF m
|
|
31.12.21
|
Rating category
|
|
0–1
|
2–3
|
4–5
|
6–8
|
9–13
|
Credit-impaired (defaulted)
|
Total gross carrying amount
|
ECL allowances
|
Net carrying amount (maximum exposure to credit risk)
|
Financial
instruments measured at amortized cost
|
|
|
|
|
|
|
|
|
|
|
Cash and balances
at central banks
|
|
48,939
|
73
|
0
|
0
|
0
|
0
|
49,012
|
0
|
49,012
|
of which: stage 1
|
|
48,939
|
73
|
0
|
0
|
0
|
0
|
49,012
|
0
|
49,012
|
Due from banks
|
|
425
|
29,548
|
414
|
0
|
4
|
0
|
30,391
|
(5)
|
30,386
|
of which: stage 1
|
|
425
|
29,548
|
414
|
0
|
4
|
0
|
30,391
|
(5)
|
30,386
|
Receivables from
securities financing transactions
|
|
12,748
|
8,016
|
7,527
|
21,763
|
1,308
|
0
|
51,362
|
(2)
|
51,360
|
of which: stage 1
|
|
12,748
|
8,016
|
7,527
|
21,763
|
1,308
|
0
|
51,362
|
(2)
|
51,360
|
Due from customers
|
|
2,841
|
31,719
|
13,302
|
60,868
|
2,156
|
360
|
111,247
|
(195)
|
111,052
|
of which: stage 1
|
|
2,841
|
31,717
|
12,978
|
60,176
|
1,641
|
0
|
109,353
|
(51)
|
109,302
|
of which: stage 2
|
|
0
|
2
|
324
|
692
|
516
|
0
|
1,533
|
(9)
|
1,524
|
of which: stage 3
|
|
0
|
0
|
0
|
0
|
0
|
360
|
360
|
(134)
|
225
|
Funding provided
to significant regulated subsidiaries eligible as total loss-absorbing
capacity
|
|
0
|
25,127
|
0
|
0
|
0
|
0
|
25,127
|
(29)
|
25,098
|
of which: stage 1
|
|
0
|
25,127
|
0
|
0
|
0
|
0
|
25,127
|
(29)
|
25,098
|
Mortgage loans
|
|
0
|
1
|
416
|
4,485
|
1
|
108
|
5,011
|
(4)
|
5,007
|
of which: stage 1
|
|
0
|
1
|
416
|
4,485
|
1
|
0
|
4,903
|
0
|
4,904
|
of which: stage 3
|
|
0
|
0
|
0
|
0
|
0
|
108
|
108
|
(4)
|
104
|
Accrued income and
prepaid expenses
|
|
43
|
205
|
298
|
531
|
30
|
0
|
1,106
|
0
|
1,106
|
of which: stage 1
|
|
43
|
205
|
298
|
530
|
29
|
0
|
1,105
|
0
|
1,105
|
of which: stage 2
|
|
0
|
0
|
0
|
1
|
1
|
0
|
1
|
0
|
1
|
Other assets
|
|
0
|
91
|
1
|
738
|
3
|
1
|
834
|
(2)
|
832
|
of which: stage 1
|
|
0
|
91
|
1
|
738
|
3
|
0
|
834
|
(1)
|
832
|
of which: stage 3
|
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
(1)
|
0
|
Total in scope of
ECL assets / ECL amounts by stages
|
|
64,996
|
94,781
|
21,958
|
88,384
|
3,501
|
468
|
274,089
|
(237)
|
273,853
|
Off-balance sheet positions and credit lines subject to expected
credit loss by rating category
|
CHF m
|
|
31.12.21
|
Rating category
|
|
0–1
|
2–3
|
4–5
|
6–8
|
9–13
|
Credit-impaired
(defaulted)
|
Total off- balance sheet exposure
(maximum exposure to credit risk)
|
ECL provisions
|
Off-balance sheet
(within the scope of ECL)
|
|
|
|
|
|
|
|
|
|
Contingent
liabilities, gross
|
|
3,997
|
9,992
|
1,624
|
1,366
|
375
|
9
|
17,364
|
(3)
|
of which: stage 1
|
|
3,997
|
9,971
|
1,577
|
1,363
|
287
|
0
|
17,194
|
(2)
|
of which: stage 2
|
|
0
|
22
|
47
|
3
|
88
|
0
|
160
|
(1)
|
of which: stage 3
|
|
0
|
0
|
0
|
0
|
0
|
9
|
9
|
0
|
Irrevocable
commitments, gross
|
|
1,621
|
4,612
|
3,023
|
1,898
|
4,701
|
4
|
15,858
|
(65)
|
of which: stage 1
|
|
1,621
|
4,369
|
2,833
|
1,602
|
4,132
|
0
|
14,557
|
(44)
|
of which: stage 2
|
|
0
|
243
|
191
|
295
|
569
|
0
|
1,298
|
(21)
|
of which: stage 3
|
|
0
|
0
|
0
|
0
|
0
|
4
|
4
|
0
|
Forward starting
transactions (securities financing transactions)
|
|
0
|
0
|
0
|
1,000
|
0
|
0
|
1,000
|
0
|
of which: stage 1
|
|
0
|
0
|
0
|
1,000
|
0
|
0
|
1,000
|
0
|
Credit lines
|
|
5
|
3,021
|
123
|
3,438
|
1,059
|
0
|
7,647
|
(2)
|
of which: stage 1
|
|
5
|
2,978
|
7
|
3,252
|
1,020
|
0
|
7,263
|
(1)
|
of which: stage 2
|
|
0
|
44
|
116
|
186
|
39
|
0
|
384
|
(1)
|
Irrevocable
committed prolongation of existing loans
|
|
0
|
671
|
0
|
0
|
0
|
0
|
671
|
0
|
of which: stage 1
|
|
0
|
671
|
0
|
0
|
0
|
0
|
671
|
0
|
Total off-balance
sheet financial instruments and credit lines
|
|
5,623
|
18,296
|
4,771
|
7,702
|
6,135
|
13
|
42,540
|
(70)
|
UBS AG standalone
financial statements (audited) 23
Note 14 Trading
portfolio and other financial instruments measured at fair value
|
|
USD m
|
|
CHF m
|
|
|
31.12.22
|
31.12.21
|
|
31.12.22
|
31.12.21
|
|
|
|
|
|
|
|
Assets
|
|
|
|
|
|
|
Trading portfolio
assets
|
|
98,566
|
119,795
|
|
91,104
|
109,213
|
of which: debt
instruments1
|
|
12,088
|
18,045
|
|
11,173
|
16,451
|
of which: listed
|
|
9,618
|
12,750
|
|
8,890
|
11,624
|
of which: equity
instruments
|
|
83,720
|
98,424
|
|
77,382
|
89,730
|
of which: precious
metals and other physical commodities
|
|
2,757
|
3,326
|
|
2,549
|
3,032
|
Total assets
measured at fair value
|
|
98,566
|
119,795
|
|
91,104
|
109,213
|
of which: fair
value derived using a valuation model
|
|
9,635
|
15,028
|
|
8,906
|
13,700
|
of which: securities
eligible for repurchase transactions in accordance with liquidity regulations
2
|
|
5,635
|
7,042
|
|
5,208
|
6,420
|
|
|
|
|
|
|
|
Liabilities
|
|
|
|
|
|
|
Trading portfolio
liabilities
|
|
25,058
|
25,711
|
|
23,160
|
23,440
|
of which: debt
instruments1
|
|
8,234
|
7,549
|
|
7,610
|
6,882
|
of which: listed
|
|
7,738
|
7,293
|
|
7,153
|
6,649
|
of which: equity
instruments
|
|
16,824
|
18,162
|
|
15,550
|
16,557
|
Financial
liabilities designated at fair value3
|
|
70,603
|
73,081
|
|
65,258
|
66,625
|
Total liabilities
measured at fair value
|
|
95,661
|
98,791
|
|
88,418
|
90,065
|
of which: fair
value derived using a valuation model
|
|
75,024
|
78,092
|
|
69,344
|
71,194
|
1 Includes money market paper. 2 Consists of high-quality
liquid debt securities that are eligible for repurchase transactions at the
Swiss National Bank or other central banks. 3 Refer to Note 20 for more
information.
|
UBS AG standalone
financial statements (audited) 24
Note 15 Derivative instruments1
|
|
31.12.22
|
|
31.12.21
|
USD bn
|
|
Derivative
financial
assets
|
Derivative
financial
liabilities
|
|
Total notional values2
|
|
Derivative
financial
assets
|
Derivative
financial
liabilities
|
|
Total notional values
|
Interest rate
contracts
|
|
|
|
|
|
|
|
|
|
|
Forwards3
|
|
0.3
|
0.2
|
|
821
|
|
0.1
|
0.3
|
|
476
|
Swaps
|
|
28.8
|
22.9
|
|
10,336
|
|
27.7
|
20.5
|
|
8,266
|
of which: designated
in hedge accounting relationships
|
|
0.0
|
0.0
|
|
112
|
|
0.0
|
0.0
|
|
115
|
Futures
|
|
0.0
|
0.0
|
|
603
|
|
0.0
|
0.0
|
|
524
|
Over-the-counter
(OTC) options
|
|
14.2
|
17.5
|
|
1,393
|
|
6.6
|
9.2
|
|
1,100
|
Exchange-traded
options
|
|
0.2
|
0.2
|
|
136
|
|
0.1
|
0.1
|
|
196
|
Total
|
|
43.6
|
40.8
|
|
13,2894
|
|
34.6
|
30.1
|
|
10,562
|
Foreign exchange
contracts
|
|
|
|
|
|
|
|
|
|
|
Forwards
|
|
26.5
|
28.6
|
|
1,765
|
|
23.8
|
23.8
|
|
2,053
|
of which: designated
in hedge accounting relationships
|
|
0.0
|
0.0
|
|
0
|
|
0.0
|
0.0
|
|
0
|
Swaps
|
|
50.2
|
51.0
|
|
3,351
|
|
24.7
|
25.1
|
|
3,246
|
of which: designated
in hedge accounting relationships
|
|
0.8
|
0.5
|
|
33
|
|
0.1
|
0.4
|
|
40
|
Futures
|
|
0.0
|
0.0
|
|
2
|
|
0.0
|
0.0
|
|
1
|
Over-the-counter
(OTC) options
|
|
9.3
|
9.3
|
|
1,074
|
|
5.2
|
5.3
|
|
823
|
Exchange-traded
options
|
|
0.1
|
0.2
|
|
10
|
|
0.0
|
0.1
|
|
10
|
Total
|
|
86.1
|
89.1
|
|
6,201
|
|
53.8
|
54.3
|
|
6,134
|
Equity contracts
|
|
|
|
|
|
|
|
|
|
|
Forwards
|
|
0.2
|
0.3
|
|
33
|
|
0.3
|
0.3
|
|
27
|
Swaps
|
|
5.7
|
6.9
|
|
223
|
|
5.0
|
9.7
|
|
279
|
Futures
|
|
0.0
|
0.0
|
|
50
|
|
0.0
|
0.0
|
|
67
|
Over-the-counter
(OTC) options
|
|
2.8
|
4.6
|
|
144
|
|
4.8
|
6.5
|
|
170
|
Exchange-traded
options
|
|
8.7
|
9.6
|
|
525
|
|
12.1
|
12.5
|
|
636
|
Total
|
|
17.4
|
21.4
|
|
975
|
|
22.3
|
29.1
|
|
1,178
|
Credit derivative
contracts
|
|
|
|
|
|
|
|
|
|
|
Credit default
swaps
|
|
0.9
|
1.0
|
|
76
|
|
1.2
|
1.4
|
|
88
|
Total return swaps
|
|
0.1
|
0.2
|
|
1
|
|
0.1
|
0.2
|
|
3
|
Other
|
|
0.0
|
0.0
|
|
2
|
|
0.0
|
0.0
|
|
5
|
Total
|
|
1.0
|
1.2
|
|
79
|
|
1.3
|
1.6
|
|
95
|
Commodity, precious
metals and other contracts
|
|
|
|
|
|
|
|
|
|
|
Forwards5
|
|
0.1
|
0.1
|
|
64
|
|
0.1
|
0.1
|
|
51
|
Swaps
|
|
0.5
|
0.7
|
|
39
|
|
0.5
|
0.8
|
|
45
|
Futures
|
|
0.0
|
0.0
|
|
16
|
|
0.0
|
0.0
|
|
14
|
Over-the-counter
(OTC) options
|
|
0.4
|
0.3
|
|
29
|
|
0.4
|
0.2
|
|
24
|
Exchange-traded
options
|
|
0.3
|
0.3
|
|
6
|
|
0.6
|
0.4
|
|
2
|
Total
|
|
1.3
|
1.4
|
|
154
|
|
1.5
|
1.5
|
|
138
|
Total before
netting
|
|
149.5
|
153.8
|
|
20,698
|
|
113.4
|
116.6
|
|
18,107
|
of which: trading
derivatives
|
|
148.6
|
153.3
|
|
|
|
113.3
|
116.2
|
|
|
of which: fair
value derived using a valuation model
|
|
147.8
|
152.4
|
|
|
|
112.7
|
115.6
|
|
|
of which:
derivatives designated in hedge accounting relationships
|
|
0.8
|
0.5
|
|
|
|
0.1
|
0.4
|
|
|
of which: fair
value derived using a valuation model
|
|
0.8
|
0.5
|
|
|
|
0.1
|
0.4
|
|
|
Netting with cash
collateral payables / receivables
|
|
(20.9)
|
(22.5)
|
|
|
|
(13.9)
|
(14.8)
|
|
|
Replacement value
netting
|
|
(113.8)
|
(113.8)
|
|
|
|
(87.6)
|
(87.6)
|
|
|
Total after
netting
|
|
14.7
|
17.4
|
|
|
|
11.9
|
14.1
|
|
|
of which: with
central clearing counterparties
|
|
0.9
|
0.2
|
|
|
|
0.5
|
0.4
|
|
|
of which: with
bank and broker-dealer counterparties
|
|
4.3
|
2.8
|
|
|
|
4.0
|
3.0
|
|
|
of which: other
client counterparties
|
|
9.6
|
14.5
|
|
|
|
7.5
|
10.7
|
|
|
1 Bifurcated embedded derivatives are presented on the same
balance sheet lines as their host contracts and are excluded from this table.
The replacement values and related notional values of these derivatives were
not material for the periods presented. 2 Total notional values include USD
11trn (31 December 2021: USD 9trn) relating to derivatives that are cleared
through either a central counterparty or an exchange. The fair value of these
derivatives net of the corresponding cash margin was not material for any of
the periods presented. 3 Includes forward rate agreements. 4
Notional amounts related to interest rate contracts increased by USD 2.7trn
compared with 31 December 2021, mainly reflecting higher business volumes
driven by elevated interest rate volatility and inflation, partly offset by
compression activity. 5 Includes derivative loan commitments with
notional values of USD 5bn as of 31 December 2022 (31 December
2021: USD 9bn) and negative replacement values of USD 43m
(31 December 2021: USD 33m).
|
UBS AG standalone
financial statements (audited) 25
Note 15 Derivative
instruments (continued)1
|
|
31.12.22
|
|
31.12.21
|
CHF bn
|
|
Derivative
financial
assets
|
Derivative
financial
liabilities
|
|
Total notional values2
|
|
Derivative
financial
assets
|
Derivative
financial
liabilities
|
|
Total notional values
|
Interest rate
contracts
|
|
|
|
|
|
|
|
|
|
|
Forwards3
|
|
0.3
|
0.1
|
|
759
|
|
0.1
|
0.2
|
|
434
|
Swaps
|
|
26.7
|
21.1
|
|
9,553
|
|
25.3
|
18.7
|
|
7,536
|
of which:
designated in hedge accounting relationships
|
|
0.0
|
0.0
|
|
104
|
|
0.0
|
0.0
|
|
105
|
Futures
|
|
0.0
|
0.0
|
|
558
|
|
0.0
|
0.0
|
|
477
|
Over-the-counter
(OTC) options
|
|
13.1
|
16.2
|
|
1,288
|
|
6.1
|
8.4
|
|
1,003
|
Exchange-traded
options
|
|
0.2
|
0.2
|
|
126
|
|
0.1
|
0.1
|
|
179
|
Total
|
|
40.3
|
37.7
|
|
12,2834
|
|
31.5
|
27.4
|
|
9,629
|
Foreign exchange
contracts
|
|
|
|
|
|
|
|
|
|
|
Forwards
|
|
24.5
|
26.5
|
|
1,631
|
|
21.7
|
21.7
|
|
1,872
|
of which:
designated in hedge accounting relationships
|
|
0.0
|
0.0
|
|
0
|
|
0.0
|
0.0
|
|
0
|
Swaps
|
|
46.4
|
47.1
|
|
3,097
|
|
22.5
|
22.9
|
|
2,960
|
of which: designated
in hedge accounting relationships
|
|
0.8
|
0.5
|
|
31
|
|
0.1
|
0.3
|
|
36
|
Futures
|
|
0.0
|
0.0
|
|
2
|
|
0.0
|
0.0
|
|
1
|
Over-the-counter
(OTC) options
|
|
8.6
|
8.6
|
|
993
|
|
4.7
|
4.8
|
|
750
|
Exchange-traded
options
|
|
0.1
|
0.2
|
|
9
|
|
0.0
|
0.1
|
|
9
|
Total
|
|
79.6
|
82.3
|
|
5,732
|
|
49.0
|
49.5
|
|
5,592
|
Equity contracts
|
|
|
|
|
|
|
|
|
|
|
Forwards
|
|
0.2
|
0.3
|
|
31
|
|
0.3
|
0.3
|
|
25
|
Swaps
|
|
5.2
|
6.3
|
|
206
|
|
4.6
|
8.9
|
|
254
|
Futures
|
|
0.0
|
0.0
|
|
46
|
|
0.0
|
0.0
|
|
61
|
Over-the-counter
(OTC) options
|
|
2.6
|
4.2
|
|
133
|
|
4.4
|
6.0
|
|
155
|
Exchange-traded
options
|
|
8.1
|
8.9
|
|
486
|
|
11.0
|
11.4
|
|
580
|
Total
|
|
16.1
|
19.8
|
|
901
|
|
20.3
|
26.5
|
|
1,074
|
Credit derivative
contracts
|
|
|
|
|
|
|
|
|
|
|
Credit default
swaps
|
|
0.8
|
0.9
|
|
70
|
|
1.1
|
1.3
|
|
80
|
Total return swaps
|
|
0.1
|
0.2
|
|
1
|
|
0.1
|
0.2
|
|
3
|
Other
|
|
0.0
|
0.0
|
|
2
|
|
0.0
|
0.0
|
|
4
|
Total
|
|
1.0
|
1.1
|
|
73
|
|
1.2
|
1.4
|
|
87
|
Commodity,
precious metals and other contracts
|
|
|
|
|
|
|
|
|
|
|
Forwards5
|
|
0.1
|
0.1
|
|
59
|
|
0.1
|
0.1
|
|
47
|
Swaps
|
|
0.5
|
0.6
|
|
36
|
|
0.4
|
0.7
|
|
41
|
Futures
|
|
0.0
|
0.0
|
|
15
|
|
0.0
|
0.0
|
|
13
|
Over-the-counter
(OTC) options
|
|
0.4
|
0.3
|
|
27
|
|
0.4
|
0.2
|
|
22
|
Exchange-traded
options
|
|
0.3
|
0.3
|
|
5
|
|
0.5
|
0.4
|
|
2
|
Total
|
|
1.2
|
1.3
|
|
142
|
|
1.4
|
1.4
|
|
125
|
Total before
netting
|
|
138.1
|
142.1
|
|
19,131
|
|
103.4
|
106.3
|
|
16,508
|
of which: trading
derivatives
|
|
137.4
|
141.7
|
|
|
|
103.3
|
106.0
|
|
|
of which: fair
value derived using a valuation model
|
|
136.6
|
140.8
|
|
|
|
102.8
|
105.4
|
|
|
of which:
derivatives designated in hedge accounting relationships
|
|
0.8
|
0.5
|
|
|
|
0.1
|
0.3
|
|
|
of which: fair
value derived using a valuation model
|
|
0.8
|
0.5
|
|
|
|
0.1
|
0.3
|
|
|
Netting with cash
collateral payables / receivables
|
|
(19.3)
|
(20.8)
|
|
|
|
(12.7)
|
(13.5)
|
|
|
Replacement value
netting
|
|
(105.2)
|
(105.2)
|
|
|
|
(79.9)
|
(79.9)
|
|
|
Total after
netting
|
|
13.6
|
16.1
|
|
|
|
10.9
|
12.9
|
|
|
of which: with
central clearing counterparties
|
|
0.8
|
0.2
|
|
|
|
0.5
|
0.4
|
|
|
of which: with
bank and broker-dealer counterparties
|
|
4.0
|
2.6
|
|
|
|
3.6
|
2.7
|
|
|
of which: other
client counterparties
|
|
8.8
|
13.4
|
|
|
|
6.8
|
9.8
|
|
|
1 Bifurcated embedded derivatives are presented on the same
balance sheet lines as their host contracts and are excluded from this table.
The replacement values and related notional values of these derivatives were
not material for the periods presented. 2 Total notional values include
CHF 10trn (31 December 2021: CHF 8trn) relating to derivatives that are
cleared through either a central counterparty or an exchange. The fair value
of these derivatives net of the corresponding cash margin was not material
for any of the periods presented. 3 Includes forward rate agreements. 4
Notional amounts related to interest rate contracts increased by CHF 2.7trn
compared with 31 December 2021, mainly reflecting higher business volumes
driven by elevated interest rate volatility and inflation, partly offset by
compression activity. 5 Includes derivative loan commitments with notional
values of CHF 4bn as of 31 December 2022 (31 December 2021: CHF 8bn) and
negative replacement values of CHF 40m (31 December 2021: CHF 30m).
|
UBS AG standalone
financial statements (audited) 26
Note 16a
Financial investments by instrument type
|
|
31.12.22
|
|
31.12.21
|
USD m
|
|
Carrying amount
|
Fair value
|
|
Carrying amount
|
Fair value
|
Debt instruments
|
|
43,725
|
43,496
|
|
19,423
|
19,801
|
of which: held to
maturity
|
|
21,657
|
21,202
|
|
6,968
|
7,039
|
of which:
available for sale
|
|
22,068
|
22,293
|
|
12,455
|
12,762
|
Equity instruments
|
|
20
|
22
|
|
58
|
67
|
of which:
qualified participations 1
|
|
4
|
4
|
|
25
|
31
|
Other
|
|
1
|
1
|
|
1
|
1
|
Total financial
investments
|
|
43,746
|
43,518
|
|
19,482
|
19,870
|
of which:
securities eligible for repurchase transactions in accordance with liquidity
regulations 2
|
|
38,452
|
38,020
|
|
16,253
|
16,332
|
1 Qualified participations are investments in which UBS AG holds
10% or more of the total capital or has at least 10% of total voting
rights. 2 Consists of high-quality liquid debt securities that are
eligible for repurchase transactions at the Swiss National Bank or other
central banks.
|
|
|
31.12.22
|
|
31.12.21
|
CHF m
|
|
Carrying amount
|
Fair value
|
|
Carrying amount
|
Fair value
|
Debt instruments
|
|
40,414
|
40,203
|
|
17,707
|
18,052
|
of which: held to
maturity
|
|
20,018
|
19,597
|
|
6,353
|
6,417
|
of which:
available for sale
|
|
20,397
|
20,606
|
|
11,354
|
11,635
|
Equity instruments
|
|
18
|
20
|
|
53
|
61
|
of which:
qualified participations 1
|
|
4
|
4
|
|
23
|
28
|
Other
|
|
1
|
1
|
|
1
|
1
|
Total financial
investments
|
|
40,434
|
40,224
|
|
17,761
|
18,115
|
of which:
securities eligible for repurchase transactions in accordance with liquidity
regulations 2
|
|
35,541
|
35,142
|
|
14,817
|
14,890
|
1 Qualified participations are investments in which UBS AG holds
10% or more of the total capital or has at least 10% of total voting
rights. 2 Consists of high-quality liquid debt securities that are
eligible for repurchase transactions at the Swiss National Bank or other
central banks.
|
Note 16b Financial investments by counterparty rating – debt
instruments
|
|
USD m
|
|
CHF m
|
|
|
31.12.22
|
31.12.21
|
|
31.12.22
|
31.12.21
|
Internal UBS
rating1
|
|
|
|
|
|
|
0–1
|
|
36,214
|
14,047
|
|
33,472
|
12,806
|
2–3
|
|
7,193
|
5,365
|
|
6,649
|
4,891
|
4–5
|
|
237
|
0
|
|
219
|
0
|
6–8
|
|
0
|
0
|
|
0
|
0
|
9–13
|
|
0
|
0
|
|
0
|
0
|
Non-rated
|
|
81
|
11
|
|
75
|
10
|
Total financial
investments
|
|
43,725
|
19,423
|
|
40,414
|
17,707
|
1 Refer to Note 19 for more information.
|
|
|
|
|
|
USD m
|
|
CHF m
|
|
|
31.12.22
|
31.12.21
|
|
31.12.22
|
31.12.21
|
Deferral position
for hedging instruments
|
|
9,029
|
0
|
|
8,346
|
0
|
Deposits and
collateral provided in connection with litigation, regulatory and similar
matters1
|
|
2,197
|
1,515
|
|
2,030
|
1,381
|
Fee- and
commission-related receivables
|
|
121
|
240
|
|
112
|
218
|
Net assets for
defined benefit plans
|
|
322
|
232
|
|
298
|
211
|
VAT, withholding
tax and other tax receivables
|
|
1,038
|
157
|
|
959
|
143
|
Other
|
|
809
|
784
|
|
746
|
714
|
of which: other
receivables due from UBS Group AG and subsidiaries in the UBS Group
|
|
519
|
477
|
|
480
|
436
|
Total other assets2
|
|
13,516
|
2,927
|
|
12,491
|
2,667
|
1 Refer to item 1 in Note 17b to the UBS AG consolidated
financial statements in the UBS Group AG and UBS AG Annual Report 2022 for
more information. 2 Includes components of other receivables due from
UBS Group AG and subsidiaries in the UBS Group and other assets totaling USD
939m (CHF 867m) as of 31 December 2022 (USD 912m (CHF 832m) as of
31 December 2021), which are within the scope of expected credit loss
accounting. Refer to Note 13d for more information.
|
UBS AG standalone
financial statements (audited) 27
Note 17b
Other liabilities
|
|
USD m
|
|
CHF m
|
|
|
31.12.22
|
31.12.21
|
|
31.12.22
|
31.12.21
|
Deferral position
for hedging instruments
|
|
0
|
630
|
|
0
|
575
|
Settlement and
clearing accounts
|
|
102
|
105
|
|
95
|
96
|
Net defined
benefit liabilities
|
|
65
|
83
|
|
60
|
75
|
VAT, withholding
tax and other tax payables1
|
|
70
|
79
|
|
65
|
72
|
Other
|
|
1,345
|
1,408
|
|
1,243
|
1,283
|
of which: other
payables due to UBS Group AG and subsidiaries in the UBS Group
|
|
814
|
960
|
|
753
|
876
|
Total other
liabilities
|
|
1,582
|
2,305
|
|
1,462
|
2,100
|
1 Excludes capital tax payables.
|
|
|
|
The table below provides information about pledged
assets, other than assets placed with central banks related to undrawn credit
lines and for payment, clearing and settlement purposes (31 December 2022:
USD 5.2bn (CHF 4.8bn), 31 December 2021: USD 4.4bn (CHF 4.0bn))
and those pledged in connection with securities financing transactions (refer
to Note 11 for more information).
|
31.12.22
|
|
31.12.21
|
USD m
|
Carrying amount of
pledged assets
|
|
Carrying amount of
pledged assets
|
Securities1
|
4,733
|
|
4,609
|
Property2
|
2,052
|
|
2,392
|
Total pledged
assets
|
6,785
|
|
7,002
|
1 Includes securities pledged for derivative transactions, where
the replacement values are managed on a portfolio basis across counterparties
and product types, and therefore there is no direct relationship between the
specific collateral pledged and the associated liability. 2 These pledged
properties serve as collateral for an existing mortgage loan from UBS
Switzerland AG, the carrying amount of which was USD 2,651m as of 31
December 2022 (USD 2,879m as of 31 December 2021).
|
|
31.12.22
|
|
31.12.21
|
CHF m
|
Carrying amount of
pledged assets
|
|
Carrying amount of
pledged assets
|
Securities1
|
4,374
|
|
4,202
|
Property2
|
1,897
|
|
2,181
|
Total pledged
assets
|
6,271
|
|
6,383
|
1 Includes securities pledged for derivative transactions, where
the replacement values are managed on a portfolio basis across counterparties
and product types, and therefore there is no direct relationship between the
specific collateral pledged and the associated liability. 2 These pledged
properties serve as collateral for an existing mortgage loan from UBS
Switzerland AG, the carrying amount of which was CHF 2,450m as of 31
December 2022 (CHF 2,625m as of 31 December 2021).
|
UBS AG standalone
financial statements (audited) 28
Note 19
Country risk of total assets
The table below provides a breakdown of total non-Swiss
assets by credit rating, after netting of assets and liabilities as recognized
on the balance sheet, but before other risk mitigants. The credit ratings reflect
the sovereign credit rating of the country to which the ultimate risk of the
underlying asset is related. The ultimate country of risk for unsecured loan
positions is the domicile of the immediate borrower or, in the case of a legal
entity, the domicile of the ultimate parent entity. For collateralized or guaranteed
positions, the ultimate country of risk is the domicile of the provider of the
collateral or guarantor or, if applicable, the domicile of the ultimate parent
entity of the provider of the collateral or guarantor. For mortgage loans, the
ultimate country of risk is the country where the real estate is located.
Similarly, the ultimate country of risk for property and equipment is the
country where the property and equipment are located. Assets for which
Switzerland is the ultimate country of risk are provided separately at the bottom
of the table in order to provide a reconciliation to total balance sheet
assets.
› Refer to the “Risk management and control” section of the UBS
Group AG and UBS AG Annual Report 2022 for more information
|
|
|
|
|
|
|
31.12.22
|
|
31.12.21
|
Classification
|
Internal UBS
rating1
|
Description
|
Moody’s Investors
Service
|
S&P
|
Fitch
|
|
USD m
|
%
|
|
USD m
|
%
|
Low risk
|
0 and 1
|
Investment grade
|
Aaa
|
AAA
|
AAA
|
|
230,979
|
46
|
|
235,039
|
46
|
2
|
|
Aa1 to Aa3
|
AA+ to AA–
|
AA+ to AA–
|
|
96,069
|
19
|
|
115,906
|
23
|
Medium risk
|
3
|
|
A1 to A3
|
A+ to A–
|
A+ to A–
|
|
71,856
|
14
|
|
71,763
|
14
|
4
|
|
Baa1 to Baa2
|
BBB+ to BBB
|
BBB+ to BBB
|
|
8,013
|
2
|
|
11,065
|
2
|
5
|
|
Baa3
|
BBB–
|
BBB–
|
|
6,156
|
1
|
|
6,297
|
1
|
High risk
|
6
|
Sub-investment
grade
|
Ba1
|
BB+
|
BB+
|
|
287
|
0
|
|
1,146
|
0
|
7
|
|
Ba2
|
BB
|
BB
|
|
566
|
0
|
|
599
|
0
|
8
|
|
Ba3
|
BB–
|
BB–
|
|
1,958
|
0
|
|
2,363
|
0
|
9
|
|
B1
|
B+
|
B+
|
|
868
|
0
|
|
1,015
|
0
|
Very high risk
|
10
|
|
B2
|
B
|
B
|
|
524
|
0
|
|
914
|
0
|
11
|
|
B3
|
B–
|
B–
|
|
20
|
0
|
|
126
|
0
|
12
|
|
Caa1 to Caa2
|
CCC+ to CCC
|
CCC+ to CCC
|
|
203
|
0
|
|
254
|
0
|
13
|
|
Caa3 to C
|
CCC– to C
|
CCC– to C
|
|
140
|
0
|
|
41
|
0
|
Distressed
|
Default
|
Defaulted
|
|
D
|
D
|
|
9
|
0
|
|
34
|
0
|
Subtotal
|
|
|
|
|
|
|
417,648
|
83
|
|
446,561
|
88
|
Switzerland
|
|
|
|
|
|
|
87,119
|
17
|
|
63,288
|
12
|
Total assets
|
|
|
|
|
|
|
504,767
|
100
|
|
509,851
|
100
|
1 Internal ratings
are mapped to the external ratings in line with the table published in the
“Risk management and control” section of the UBS Group AG and UBS AG Annual
Report 2022.
|
|
|
|
|
|
|
|
31.12.22
|
|
31.12.21
|
Classification
|
Internal UBS
rating1
|
Description
|
Moody’s Investors
Service
|
S&P
|
Fitch
|
|
CHF m
|
%
|
|
CHF m
|
%
|
Low risk
|
0 and 1
|
Investment grade
|
Aaa
|
AAA
|
AAA
|
|
213,488
|
46
|
|
214,277
|
46
|
2
|
|
Aa1 to Aa3
|
AA+ to AA–
|
AA+ to AA–
|
|
88,797
|
19
|
|
105,668
|
23
|
Medium risk
|
3
|
|
A1 to A3
|
A+ to A–
|
A+ to A–
|
|
66,416
|
14
|
|
65,424
|
14
|
4
|
|
Baa1 to Baa2
|
BBB+ to BBB
|
BBB+ to BBB
|
|
7,407
|
2
|
|
10,087
|
2
|
5
|
|
Baa3
|
BBB–
|
BBB–
|
|
5,690
|
1
|
|
5,741
|
1
|
High risk
|
6
|
Sub-investment
grade
|
Ba1
|
BB+
|
BB+
|
|
265
|
0
|
|
1,044
|
0
|
7
|
|
Ba2
|
BB
|
BB
|
|
523
|
0
|
|
546
|
0
|
8
|
|
Ba3
|
BB–
|
BB–
|
|
1,810
|
0
|
|
2,154
|
0
|
9
|
|
B1
|
B+
|
B+
|
|
802
|
0
|
|
925
|
0
|
Very high risk
|
10
|
|
B2
|
B
|
B
|
|
485
|
0
|
|
834
|
0
|
11
|
|
B3
|
B–
|
B–
|
|
19
|
0
|
|
115
|
0
|
12
|
|
Caa1 to Caa2
|
CCC+ to CCC
|
CCC+ to CCC
|
|
187
|
0
|
|
232
|
0
|
13
|
|
Caa3 to C
|
CCC– to C
|
CCC– to C
|
|
129
|
0
|
|
37
|
0
|
Distressed
|
Default
|
Defaulted
|
|
D
|
D
|
|
8
|
0
|
|
31
|
0
|
Subtotal
|
|
|
|
|
|
|
386,026
|
83
|
|
407,115
|
88
|
Switzerland
|
|
|
|
|
|
|
80,524
|
17
|
|
57,698
|
12
|
Total assets
|
|
|
|
|
|
|
466,550
|
100
|
|
464,814
|
100
|
1 Internal ratings
are mapped to the external ratings in line with the table published in the
“Risk management and control” section of the UBS Group AG and UBS AG Annual
Report 2022.
|
UBS AG standalone
financial statements (audited) 29
Note 20
Structured debt instruments
The table below provides a breakdown
of financial liabilities designated at fair value that are considered
structured debt instruments.
|
|
USD m
|
|
CHF m
|
|
|
31.12.22
|
31.12.21
|
|
31.12.22
|
31.12.21
|
Fixed-rate bonds
with structured features
|
|
2,293
|
1,819
|
|
2,120
|
1,658
|
Structured debt
instruments issued:
|
|
|
|
|
|
|
Equity-linked
|
|
41,926
|
46,834
|
|
38,752
|
42,698
|
Rates-linked
|
|
15,925
|
16,152
|
|
14,719
|
14,725
|
Credit-linked
|
|
2,281
|
1,506
|
|
2,108
|
1,373
|
Commodity-linked1
|
|
4,304
|
2,913
|
|
3,978
|
2,655
|
FX-linked
|
|
578
|
412
|
|
535
|
375
|
Funding received
from UBS Group AG designated at fair value2
|
|
1,959
|
2,137
|
|
1,811
|
1,948
|
Structured
over-the-counter (OTC) debt instruments
|
|
1,336
|
1,308
|
|
1,235
|
1,193
|
Total financial
liabilities designated at fair value
|
|
70,603
|
73,081
|
|
65,258
|
66,625
|
1 Includes precious metals-linked debt instruments issued. 2
Refer to Note 21 for more information.
|
In addition to Financial liabilities designated at fair
value, certain structured debt instruments were reported within the balance
sheet lines Due to banks, Due to customers and Bonds issued.
These instruments were bifurcated for measurement purposes. As of
31 December 2022, the total carrying amount of the host instruments
was USD 5,379m (CHF 4,972m) (31 December 2021: USD 7,613m
(CHF 6,941m)) and the total carrying amount of the bifurcated embedded
derivatives was positive USD 59m (CHF 54m) (31 December 2021:
positive USD 57m (CHF 52m)).
Note 21 Funding eligible as total loss-absorbing capacity at the
UBS AG level
|
|
USD m
|
|
CHF m
|
|
|
31.12.22
|
31.12.21
|
|
31.12.22
|
31.12.21
|
Funding eligible
as total loss-absorbing capacity at the UBS AG level included in:
|
|
|
|
|
|
|
Funding received
from UBS Group AG measured at amortized cost
|
|
59,202
|
52,826
|
|
54,720
|
48,159
|
Funding received
from UBS Group AG designated at fair value
|
|
1,959
|
2,137
|
|
1,811
|
1,948
|
Bonds issued
|
|
3,041
|
3,049
|
|
2,811
|
2,780
|
Total funding
eligible as total loss-absorbing capacity at the UBS AG level1
|
|
64,202
|
58,011
|
|
59,342
|
52,887
|
1 Represents the Swiss GAAP carrying amount of instruments
qualifying as total loss-absorbing capital. In accordance with the Basel III
framework, as applicable to Swiss systemically relevant banks (SRB), total
funding eligible as total loss-absorbing capacity at the UBS AG level was USD
58,823m (CHF 54,370m) as of 31 December 2022 (31 December 2021: USD 58,089m
(CHF 52,958m)). Refer to the “UBS AG standalone regulatory information”
section of this report for more information about Swiss SRB going and gone
concern capital.
|
UBS AG standalone
financial statements (audited) 30
UBS AG shares
As of 31 December 2022, UBS AG’s share capital of
CHF 386m (unchanged from 31 December
2021) consisted of fully paid-up registered
issued shares with a nominal value each of CHF 0.10, which each entitle
the holder to one vote at the meeting of the shareholders of UBS AG, if entered
into the share register as having the right to vote, as well as a proportionate
share of distributed dividends. UBS AG’s shares are not subject to any
restrictions or limitations on their transferability.
As of 31 December 2022, shares issued by UBS AG totaled
3,858,408,466 shares (unchanged from 31 December 2021). The shares were
all dividend bearing and held by UBS Group AG.
Additionally, as of 31 December 2022, 380,000,000
registered shares with a nominal value of CHF 0.10 each were available to
be issued out of conditional capital (unchanged from 31 December 2021)
through the voluntary or mandatory exercise of conversion rights and / or
warrants granted in connection with the issuance of bonds or similar financial
instruments on national or international capital markets.
Non-distributable reserves
Non-distributable reserves consist of 50% of the share
capital of UBS AG, amounting to USD 197m (CHF 193m) as of
31 December 2022 (unchanged from 31 December 2021).
Share capital – planned conversion of nominal currency in
2023
Following revisions to Swiss
corporate law that are effective from 1 January 2023, the BoD will propose
at the 2023 AGM that the shareholder approves the conversion of the share
capital currency of UBS AG from the Swiss franc to the US dollar. As a result,
the capital contribution reserve of UBS AG would also be converted to US
dollars. This would align the share capital currency with the financial
statement presentation currency of UBS AG. If the change is approved, the
share capital of UBS AG will be slightly reduced, to a nominal value per
share of USD 0.10 (from CHF 0.10 currently), with the amount of the
reduction allocated to the capital contribution reserve. If approved, the
conversion will be implemented with retroactive effect as of 1 January
2023 for accounting purposes based on the closing exchange rate from
30 December 2022. Total equity reported for UBS AG will not change.
Note 22b
Significant shareholders
The sole direct shareholder of UBS AG is UBS Group AG,
which holds 100% of UBS AG shares. These shares are entitled to voting rights.
Indirect shareholders of UBS AG included in the table below are the direct
shareholders of UBS Group AG (acting in their own name or in their
capacity as nominees for other investors or beneficial owners) that were
registered in the UBS Group AG share register with 3% or more of the share
capital of UBS Group AG as of 31 December 2022 or as of 31 December
2021. The shares and share capital of UBS AG held by indirect shareholders, as
shown in the table below, represent their relative holding of UBS Group AG
shares. They do not have voting rights in UBS AG.
› Refer to Note 24 to the UBS Group AG standalone financial statements
in the UBS Group AG Annual Report 2022 for more information about significant
shareholders of UBS Group AG
|
|
31.12.22
|
|
31.12.21
|
USD m, except
where indicated
|
|
Share capital held
|
Shares held (%)
|
|
Share capital held
|
Shares held (%)
|
Significant direct
shareholder of UBS AG
|
|
|
|
|
|
|
UBS Group AG
|
|
393
|
100
|
|
393
|
100
|
Significant
indirect shareholders of UBS AG
|
|
|
|
|
|
|
Chase Nominees
Ltd., London
|
|
34
|
9
|
|
35
|
9
|
DTC (Cede &
Co.), New York1
|
|
28
|
7
|
|
23
|
6
|
Nortrust Nominees
Ltd., London
|
|
17
|
4
|
|
19
|
5
|
1 DTC (Cede & Co.), New York, “The Depository Trust
Company,” is a US securities clearing organization.
|
|
|
31.12.22
|
|
31.12.21
|
CHF m, except
where indicated
|
|
Share capital held
|
Shares held (%)
|
|
Share capital held
|
Shares held (%)
|
Significant direct
shareholder of UBS AG
|
|
|
|
|
|
|
UBS Group AG
|
|
386
|
100
|
|
386
|
100
|
Significant
indirect shareholders of UBS AG
|
|
|
|
|
|
|
Chase Nominees
Ltd., London
|
|
33
|
9
|
|
34
|
9
|
DTC (Cede &
Co.), New York1
|
|
27
|
7
|
|
22
|
6
|
Nortrust Nominees
Ltd., London
|
|
17
|
4
|
|
19
|
5
|
1 DTC (Cede & Co.), New York, “The Depository Trust
Company,” is a US securities clearing organization.
|
UBS AG standalone
financial statements (audited) 31
Note 23
Swiss pension plan and non-Swiss defined benefit plans
a) Assets related to non-Swiss defined benefit plans
|
|
USD m
|
|
CHF m
|
|
|
31.12.22
|
31.12.21
|
|
31.12.22
|
31.12.21
|
Net assets for
non-Swiss defined benefit plans1
|
|
322
|
232
|
|
298
|
211
|
Total assets for
non-Swiss defined benefit plans
|
|
322
|
232
|
|
298
|
211
|
1 As of 31 December 2022, USD 321m (CHF 297m)
related to the UK defined benefit pension plan and USD 1m (CHF 1m)
related to the US defined benefit pension plan. As of 31 December 2021,
USD 192m (CHF 175m) related to the UK defined benefit pension plan
and USD 39m (CHF 36m) related to the US defined benefit pension
plan.
|
|
|
|
|
b) Liabilities related to Swiss pension plan and non-Swiss
defined benefit plans
|
|
USD m
|
|
CHF m
|
|
|
31.12.22
|
31.12.21
|
|
31.12.22
|
31.12.21
|
Provision for
Swiss pension plan
|
|
0
|
0
|
|
0
|
0
|
Net defined
benefit liabilities for non-Swiss defined benefit plans1
|
|
65
|
83
|
|
60
|
75
|
Total provision
for Swiss pension plan and net defined benefit liabilities for non-Swiss
defined benefit plans
|
|
65
|
83
|
|
60
|
75
|
Bank accounts at
UBS and UBS debt instruments held by Swiss pension fund
|
|
24
|
15
|
|
22
|
14
|
UBS derivative
financial instruments held by Swiss pension fund
|
|
7
|
10
|
|
6
|
9
|
Total liabilities
related to Swiss pension plan and non-Swiss defined benefit plans
|
|
95
|
108
|
|
88
|
98
|
1 As of 31 December 2022, USD 37m (CHF 34m) related to
the US plans and USD 14m (CHF 13m) related to the UK plan. As of 31
December 2021, USD 44m (CHF 40m) related to the US plans and
USD 22m (CHF 20m) related to the UK plan.
|
|
|
|
|
c) Swiss pension plan
|
|
|
|
|
|
|
|
|
USD m
|
|
CHF m
|
|
|
As of or for the year ended
|
|
|
31.12.22
|
31.12.21
|
|
31.12.22
|
31.12.21
|
Pension plan
surplus1
|
|
297
|
588
|
|
275
|
536
|
Economic benefit /
(obligation) of UBS AG
|
|
0
|
0
|
|
0
|
0
|
Change in economic
benefit / (obligation) recognized in the income statement
|
|
0
|
0
|
|
0
|
0
|
Employer
contributions in the period recognized in the income statement
|
|
41
|
52
|
|
39
|
47
|
Performance
awards-related employer contributions accrued
|
|
4
|
5
|
|
4
|
5
|
Total pension
expense recognized in the income statement within Personnel expenses
|
|
45
|
58
|
|
42
|
52
|
1 The pension plan surplus is determined in accordance with
FER 26 and consists of the reserve for the fluctuation in asset value.
The surplus did not represent an economic benefit for UBS AG in accordance
with FER 16 both as of 31 December 2022 and 31 December 2021.
|
UBS AG has elected to apply FER 16 for its Swiss
pension plan and IFRS (IAS 19) for its non-Swiss defined benefit plans.
However, remeasurements of the defined benefit obligations for non-Swiss
defined benefit plans are recognized in the income statement rather than
directly in equity.
In 2022, a credit of USD 55m (CHF 51m) was recognized in the
income statement, driven by a net gain related to the UK defined benefit plan
that reflected an increase in the applicable discount rate, partly offset by a
loss due to a negative return on plan assets and an increase in the applicable
inflation rate. This net gain was partly offset by expenses related to the
Swiss plan and other non-Swiss defined benefit plans.
› Refer to Note 2 for more information
› Refer to Note 26 to the UBS AG consolidated financial statements
in the UBS Group AG and UBS AG Annual Report 2022 for more information about non-Swiss
defined benefit plans in accordance with IFRS
The Swiss pension plan had no employer contribution reserve as
of both 31 December 2022 and 31 December 2021.
UBS AG standalone
financial statements (audited) 32
Transactions with related parties are conducted at
internally agreed transfer prices or at arm’s-length terms and neither involve
more than the normal risk of collectability nor contain any other unfavorable
features for the firm. Loans, fixed advances and mortgages granted to
non-independent members of the governing bodies in the ordinary course of
business are also on substantially the same terms and conditions that are
available to other employees, including interest rates and collateral.
Independent members of the governing bodies are granted loans and mortgages in
the ordinary course of business at general market conditions.
|
|
31.12.22
|
|
31.12.21
|
USD m
|
|
Amounts due from
|
|
Amounts due to
|
|
Amounts due from
|
|
Amounts due to
|
Qualified
shareholders1
|
|
2,609
|
|
65,310
|
|
725
|
|
62,245
|
of which: due from
/ to customers
|
|
2,526
|
|
1,061
|
|
672
|
|
2,030
|
of which: funding
received from UBS Group AG measured at amortized cost
|
|
|
|
61,202
|
|
|
|
57,078
|
of which: funding
received from UBS Group AG designated at fair value
|
|
|
|
1,959
|
|
|
|
2,137
|
Subsidiaries
|
|
100,990
|
|
51,093
|
|
93,934
|
|
49,574
|
of which: due from
/ to banks
|
|
26,500
|
|
39,168
|
|
28,062
|
|
31,602
|
of which: due from
/ to customers
|
|
32,075
|
|
2,801
|
|
26,596
|
|
2,279
|
of which:
receivables / payables from securities financing transactions
|
|
13,003
|
|
7,775
|
|
9,346
|
|
13,880
|
of which: funding
provided to significant regulated subsidiaries eligible as total
loss-absorbing capacity
|
|
27,678
|
|
|
|
27,530
|
|
|
Affiliated
entities2
|
|
332
|
|
420
|
|
345
|
|
336
|
of which: due from
/ to customers
|
|
219
|
|
208
|
|
316
|
|
130
|
Members of
governing bodies3
|
|
33
|
|
|
|
34
|
|
|
External auditors
|
|
|
|
4
|
|
|
|
4
|
Other related
parties4
|
|
6
|
|
2
|
|
1
|
|
2
|
1 The qualified shareholder of UBS AG is UBS Group AG. 2
Affiliated entities of UBS AG are all direct subsidiaries of UBS Group
AG. 3 Members of governing bodies consist of the members of
the Board of Directors and Group Executive Board of UBS Group AG and the members
of the Board of Directors and Executive Board of UBS AG. 4 Includes
amounts due to / from other participations.
|
|
|
31.12.22
|
|
31.12.21
|
CHF m
|
|
Amounts due from
|
|
Amounts due to
|
|
Amounts due from
|
|
Amounts due to
|
Qualified
shareholders1
|
|
2,412
|
|
60,366
|
|
661
|
|
56,747
|
of which: due from
/ to customers
|
|
2,335
|
|
981
|
|
613
|
|
1,851
|
of which: funding
received from UBS Group AG measured at amortized cost
|
|
|
|
56,568
|
|
|
|
52,036
|
of which: funding
received from UBS Group AG designated at fair value
|
|
|
|
1,811
|
|
|
|
1,948
|
Subsidiaries
|
|
93,344
|
|
47,225
|
|
85,636
|
|
45,195
|
of which: due from
/ to banks
|
|
24,494
|
|
36,202
|
|
25,583
|
|
28,810
|
of which: due from
/ to customers
|
|
29,647
|
|
2,589
|
|
24,246
|
|
2,078
|
of which: receivables
/ payables from securities financing transactions
|
|
12,018
|
|
7,187
|
|
8,521
|
|
12,654
|
of which: funding
provided to significant regulated subsidiaries eligible as total
loss-absorbing capacity
|
|
25,582
|
|
|
|
25,098
|
|
|
Affiliated
entities2
|
|
307
|
|
388
|
|
314
|
|
306
|
of which: due from
/ to customers
|
|
202
|
|
193
|
|
288
|
|
118
|
Members of
governing bodies3
|
|
31
|
|
|
|
31
|
|
|
External auditors
|
|
|
|
4
|
|
|
|
3
|
Other related
parties4
|
|
5
|
|
2
|
|
1
|
|
2
|
1 The qualified shareholder of UBS AG is UBS Group AG.
2 Affiliated entities of UBS AG are all direct subsidiaries of UBS
Group AG. 3 Members of governing bodies consist of the
members of the Board of Directors and Group Executive Board of UBS Group AG
and the members of the Board of Directors and Executive Board of UBS AG. 4
Includes amounts due to / from other participations.
|
As of 31 December 2022, off-balance sheet positions
related to subsidiaries amounted to USD 8.0bn (CHF 7.4bn)
(31 December 2021: USD 9.2bn (CHF 8.4bn)), of which
USD 6.2bn (CHF 5.7bn) was guarantees to third parties (31 December
2021: USD 7.8bn (CHF 7.1bn)) and USD 0.5bn (CHF 0.5bn) was
loan commitments (31 December 2021: USD 0.8bn (CHF 0.7bn)).
UBS AG standalone
financial statements (audited) 33
Note 25
Fiduciary transactions
|
|
USD m
|
|
CHF m
|
|
|
31.12.22
|
31.12.21
|
|
31.12.22
|
31.12.21
|
Fiduciary deposits
|
|
84
|
63
|
|
78
|
57
|
of which: placed
with third-party banks
|
|
84
|
63
|
|
78
|
57
|
of which: placed
with subsidiaries and affiliated entities
|
|
0
|
0
|
|
0
|
0
|
Total fiduciary
transactions
|
|
84
|
63
|
|
78
|
57
|
Fiduciary transactions encompass transactions entered
into by UBS AG that result in holding or placing assets on behalf of
individuals, trusts, defined benefit plans and other institutions. Unless the
recognition criteria for the assets are satisfied, these assets and the related
income are excluded from UBS AG’s balance sheet and income statement but are
disclosed in this Note as off-balance sheet fiduciary transactions. Client
deposits that are initially placed as fiduciary transactions with UBS AG may be
recognized on UBS AG’s balance sheet in situations in which the deposit is
subsequently placed within UBS AG. In such cases, these deposits are not
reported in the table above.
Note 26a
Invested assets and net new money
|
|
USD bn
|
|
CHF bn
|
|
|
As of or for the year ended
|
|
As of or for the year ended
|
|
|
31.12.22
|
31.12.21
|
|
31.12.22
|
31.12.21
|
Discretionary
assets
|
|
53
|
67
|
|
48
|
61
|
Other invested
assets
|
|
415
|
493
|
|
384
|
449
|
Total invested
assets1
|
|
468
|
560
|
|
432
|
510
|
Net new money
|
|
(1)
|
18
|
|
(2)
|
16
|
1 Includes no double counts.
|
Note 26b Development
of invested assets
|
|
USD bn
|
|
CHF bn
|
|
|
31.12.22
|
31.12.21
|
|
31.12.22
|
31.12.21
|
Total invested
assets at the beginning of the year1
|
|
560
|
598
|
|
510
|
529
|
Net new money
|
|
(1)
|
18
|
|
(2)
|
16
|
Market movements2
|
|
(81)
|
(48)
|
|
(75)
|
(43)
|
Foreign currency
translation
|
|
(10)
|
(5)
|
|
(2)
|
10
|
Other effects
|
|
1
|
(3)
|
|
1
|
(2)
|
Total invested assets
at the end of the year1
|
|
468
|
560
|
|
432
|
510
|
1 Includes no double counts. 2 Includes interest and
dividend income.
|
› Refer to Note 31 to the UBS AG consolidated financial statements
in the UBS Group AG and UBS AG Annual Report 2022 for more information
UBS AG standalone
financial statements (audited) 34
UBS AG standalone
financial statements (audited) 35
UBS AG standalone
financial statements (audited) 36
UBS AG standalone
financial statements (audited) 37
UBS AG standalone
financial statements (audited) 38
UBS AG standalone
financial statements (audited) 39
UBS AG
standalone regulatory information
UBS AG
standalone regulatory information
Key metrics of the
fourth quarter of 2022
Quarterly | The table below is
based on Basel Committee on Banking Supervision (BCBS) Basel III rules.
During the fourth quarter of 2022, common equity tier 1
(CET1) capital increased by USD 0.5bn to USD 54.0bn, mainly
reflecting operating profit before tax, partly offset by additional accruals
for capital returns to UBS Group AG. Tier 1 capital decreased by
USD 1.3bn to USD 65.8bn, primarily driven by a USD 1.8bn
decrease in additional tier 1 (AT1) capital, partly offset by the
aforementioned increase in CET1 capital. The decrease in AT1 capital was mainly
driven by our announcement on 5 December 2022 that we intended to redeem
an AT1 capital instrument on 31 January 2023, the first call date (ISIN
CH0400441280, with a nominal amount of USD 2.0bn, issued on
31 January 2018). This instrument ceased to be eligible as AT1 capital
when the call was announced in December 2022. Total capital decreased by
USD 1.3bn to USD 66.3bn, mainly reflecting the aforementioned
decrease in tier 1 capital.
Phase-in risk-weighted assets (RWA) increased by USD 9.5bn to
USD 332.9bn during the fourth quarter of 2022, primarily driven by increased
participation RWA and, to a lesser extent, by increases across market risk, as
well as credit and counterparty credit risk RWA, partly offset by a decrease in
operational risk RWA.
Leverage ratio exposure increased by USD 22.2bn to
USD 575.5bn, mainly driven by higher trading portfolio assets and
purchases of high-quality liquid asset (HQLA) securities, partly offset by
lower derivatives.
Correspondingly, the CET1 capital ratio of UBS AG decreased to
16.2% from 16.5%, reflecting the increase in RWA, partly offset by the increase
in the CET1 capital. The firm’s Basel III leverage ratio decreased to
11.4% from 12.1%, reflecting the higher leverage ratio exposure and the
decrease in tier 1 capital.
The quarterly average liquidity
coverage ratio (the LCR) increase was driven by a decrease in the average net
cash outflows of USD 2.2bn to USD 53.6bn, mainly due to higher
inflows from intercompany funding to other UBS entities. The effect of the
reduction in the average net cash outflows was partially offset by a decrease in
the average HQLA of USD 4.2bn to USD 101.6bn due to higher funding
consumption from the business divisions.
As of
31 December 2022, the net stable funding ratio (the NSFR) decreased
by 0.9 percentage points to 90.8%,
remaining above the prudential requirement communicated by the Swiss Financial
Market Supervisory Authority (FINMA). The movement in the NSFR was driven by an
increase in required stable funding of USD 16.9bn
to USD 280.2bn, mainly due to higher trading
assets and loans to customers, partly offset by decreased derivative balances.
Available stable funding increased by USD 12.9bn
to USD 254.4bn, largely driven by higher customer
deposits and debt securities issued.
UBS AG standalone
regulatory information 40
KM1: Key metrics
|
|
|
|
|
|
USD m, except
where indicated
|
|
|
31.12.22
|
30.9.22
|
30.6.22
|
31.3.22
|
31.12.21
|
Available capital
(amounts)
|
|
|
|
|
|
1
|
Common Equity Tier
1 (CET1)1
|
53,995
|
53,480
|
54,146
|
52,218
|
52,818
|
1a
|
Fully loaded ECL
accounting model CET1
|
53,995
|
53,480
|
54,139
|
52,211
|
52,803
|
2
|
Tier 11
|
65,836
|
67,149
|
68,188
|
66,597
|
66,658
|
2a
|
Fully loaded ECL
accounting model Tier 1
|
65,836
|
67,149
|
68,180
|
66,589
|
66,643
|
3
|
Total capital1
|
66,321
|
67,634
|
68,682
|
67,599
|
68,054
|
3a
|
Fully loaded ECL
accounting model total capital
|
66,321
|
67,634
|
68,674
|
67,592
|
68,039
|
Risk-weighted
assets (amounts)2
|
|
|
|
|
|
4
|
Total
risk-weighted assets (RWA)
|
332,864
|
323,364
|
327,846
|
330,401
|
317,913
|
4a
|
Minimum capital
requirement3
|
26,629
|
25,869
|
26,228
|
26,432
|
25,433
|
4b
|
Total
risk-weighted assets (pre-floor)
|
332,864
|
323,364
|
327,846
|
330,401
|
317,913
|
Risk-based capital
ratios as a percentage of RWA2
|
|
|
|
|
|
5
|
CET1 ratio (%)1
|
16.22
|
16.54
|
16.52
|
15.80
|
16.61
|
5a
|
Fully loaded ECL
accounting model CET1 ratio (%)
|
16.22
|
16.54
|
16.51
|
15.80
|
16.61
|
6
|
Tier 1 ratio (%)1
|
19.78
|
20.77
|
20.80
|
20.16
|
20.97
|
6a
|
Fully loaded ECL
accounting model Tier 1 ratio (%)
|
19.78
|
20.77
|
20.80
|
20.15
|
20.96
|
7
|
Total capital
ratio (%)1
|
19.92
|
20.92
|
20.95
|
20.46
|
21.41
|
7a
|
Fully loaded ECL accounting
model total capital ratio (%)
|
19.92
|
20.92
|
20.95
|
20.46
|
21.40
|
Additional CET1
buffer requirements as a percentage of RWA
|
|
|
|
|
|
8
|
Capital
conservation buffer requirement (%)
|
2.50
|
2.50
|
2.50
|
2.50
|
2.50
|
9
|
Countercyclical
buffer requirement (%)
|
0.06
|
0.02
|
0.02
|
0.02
|
0.02
|
9a
|
Additional
countercyclical buffer for Swiss mortgage loans (%)
|
0.00
|
0.00
|
|
|
|
10
|
Bank G-SIB and /
or D-SIB additional requirements (%)4
|
|
|
|
|
|
11
|
Total of bank CET1
specific buffer requirements (%)5
|
2.56
|
2.52
|
2.52
|
2.52
|
2.52
|
12
|
CET1 available
after meeting the bank’s minimum capital requirements (%)
|
11.72
|
12.04
|
12.02
|
11.30
|
12.11
|
Basel III leverage
ratio
|
|
|
|
|
|
13
|
Total Basel III
leverage ratio exposure measure
|
575,461
|
553,215
|
569,794
|
594,893
|
593,868
|
14
|
Basel III leverage
ratio (%)1
|
11.44
|
12.14
|
11.97
|
11.19
|
11.22
|
14a
|
Fully loaded ECL
accounting model Basel III leverage ratio (%)
|
11.44
|
12.14
|
11.97
|
11.19
|
11.22
|
Liquidity coverage
ratio (LCR)6
|
|
|
|
|
|
15
|
Total high-quality
liquid assets (HQLA)
|
101,609
|
105,768
|
104,628
|
103,168
|
89,488
|
16
|
Total net cash
outflow
|
53,616
|
55,770
|
55,405
|
55,039
|
52,229
|
16a
|
of which: cash
outflows
|
156,764
|
155,688
|
159,568
|
162,735
|
163,207
|
16b
|
of which: cash inflows
|
103,148
|
99,919
|
104,163
|
107,696
|
110,978
|
17
|
LCR (%)
|
191.19
|
190.23
|
189.29
|
188.26
|
173.19
|
Net stable funding
ratio (NSFR)7
|
|
|
|
|
|
18
|
Total available
stable funding
|
254,433
|
241,505
|
244,791
|
249,760
|
257,992
|
19
|
Total required
stable funding
|
280,166
|
263,308
|
265,597
|
275,424
|
289,195
|
20
|
NSFR (%)
|
90.82
|
91.72
|
92.17
|
90.68
|
89.21
|
1 As of 1 July 2022, our capital amounts exclude the
transitional relief of recognizing ECL allowances and provisions in CET1
capital in accordance with FINMA Circular 2013/1 “Eligible capital –
banks.” 2 Based on phase-in rules for RWA. Refer to “Swiss SRB going
and gone concern requirements and information” below for more information.
3 Calculated as 8% of total RWA, based on total capital minimum requirements,
excluding CET1 buffer requirements. 4 Swiss SRB going and gone concern
requirements and information for UBS AG standalone are provided below in this
section. 5 Excludes non-BCBS capital buffer requirements for risk-weighted
positions that are directly or indirectly backed by residential properties in
Switzerland. 6 Calculated after the application of haircuts and
inflow and outflow rates, as well as, where applicable, caps on Level 2
assets and cash inflows. Calculated based on an average of 63 data points in
the fourth quarter of 2022 and 66 data points in the third quarter of 2022.
For the prior-quarter data points, refer to the respective Pillar 3
Report, available under “Pillar 3 disclosures” at ubs.com/investors, for
more information. 7 In accordance with Art. 17h para. 3 and 4 of the
Liquidity Ordinance, UBS AG standalone is required to maintain a minimum NSFR
of at least 80% without taking into account excess funding of UBS Switzerland
AG and 100% after taking into account such excess funding.
|
p
UBS AG standalone
regulatory information 41
Swiss SRB
going and gone concern requirements and information
UBS AG standalone is considered a systemically relevant bank
(an SRB) under Swiss banking law and is subject to capital regulations on a
standalone basis.
The capital requirements based on RWA include a minimum CET1
capital requirement of 10.06%, including a countercyclical buffer of 0.06%, and
a total going concern capital requirement of 14.36%, including a
countercyclical buffer of 0.06%. The capital requirements based on the leverage
ratio denominator (the LRD) include a minimum CET1 capital requirement of 3.5%
and a total going concern leverage ratio requirement of 5.0%.
CET1 and high-trigger AT1 capital instruments are eligible as
going concern capital. As of 31 December 2022, one remaining outstanding
low-trigger AT1 capital instrument, amounting to USD 1.2bn, that was on
lent from UBS Group AG to UBS AG qualifies as going concern capital, as agreed
with FINMA.
Currently, UBS AG standalone is subject to a gone concern
capital requirement based on the sum of: (i) the capital requirements
resulting from third-party exposure on a standalone basis; (ii) a buffer
requirement equal to 30% of the Group’s gone concern capital requirement on UBS
AG’s consolidated exposure; and (iii) the nominal value of the gone
concern instruments issued by UBS entities and held by the parent bank. A
transitional period until 2024 has been granted for the buffer requirement. The
gone concern capital coverage ratio reflects how much gone concern capital is
available to meet the gone concern requirement. Outstanding high- and low-trigger
loss-absorbing tier 2 capital instruments, non-Basel III-compliant
tier 2 capital instruments and total loss-absorbing capacity-eligible
senior unsecured debt instruments are eligible to meet gone concern
requirements until one year before maturity.
› Refer to “Significant regulatory developments, disclosure
requirements and other changes to be adopted after 2022” in the “Introduction
and basis for preparation” section of the 31 December 2022 Pillar 3 Report for
more information about Revisions to the Swiss Banking Ordinance
For direct and indirect investments, including the holding of
regulatory capital instruments of UBS AG by subsidiaries that are active in
banking and finance, a FINMA decree introduced a risk-weighting approach, with
a phase-in period until 1 January 2028. Starting from 1 July 2017,
these investments were risk-weighted at 200%. From 1 January 2019 onward,
the risk weights are being gradually raised by 5 percentage points per
year for Switzerland-domiciled investments and by 20 percentage points per
year for foreign-domiciled investments until the fully applied risk weights are
250% and 400%, respectively. As of 31 December 2022, the applicable
phase-in risk weights are 220% for Switzerland-domiciled investments and 280%
for foreign-domiciled investments.
› Refer to “Additional information” in the “Capital, liquidity and
funding, and balance sheet” section of the UBS Group AG Annual Report 2022 for
more information about the joint liability of UBS AG and UBS Switzerland AG
UBS AG standalone
regulatory information 42
Quarterly | The tables below provide details of the
Swiss SRB RWA- and LRD-based going and gone concern requirements and
information as required by FINMA; details regarding eligible gone concern
instruments are provided below.
Swiss SRB going and gone concern requirements and information
|
As of 31.12.22
|
|
RWA, phase-in
|
|
RWA, fully applied as of 1.1.28
|
|
LRD
|
USD m, except
where indicated
|
|
in %
|
|
|
in %
|
|
|
in %
|
|
Required going
concern capital
|
|
|
|
|
|
|
|
|
|
Total going
concern capital
|
|
14.361
|
47,800
|
|
14.361
|
56,023
|
|
5.001
|
28,773
|
Common equity tier
1 capital
|
|
10.06
|
33,486
|
|
10.06
|
39,247
|
|
3.50
|
20,141
|
of which: minimum
capital
|
|
4.50
|
14,979
|
|
4.50
|
17,556
|
|
1.50
|
8,632
|
of which: buffer
capital
|
|
5.50
|
18,307
|
|
5.50
|
21,457
|
|
2.00
|
11,509
|
of which: countercyclical
buffer
|
|
0.06
|
200
|
|
0.06
|
234
|
|
|
|
Maximum additional
tier 1 capital
|
|
4.30
|
14,313
|
|
4.30
|
16,776
|
|
1.50
|
8,632
|
of which:
additional tier 1 capital
|
|
3.50
|
11,650
|
|
3.50
|
13,654
|
|
1.50
|
8,632
|
of which:
additional tier 1 buffer capital
|
|
0.80
|
2,663
|
|
0.80
|
3,121
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Eligible going
concern capital
|
|
|
|
|
|
|
|
|
|
Total going
concern capital
|
|
19.78
|
65,836
|
|
16.88
|
65,836
|
|
11.44
|
65,836
|
Common equity tier
1 capital
|
|
16.22
|
53,995
|
|
13.84
|
53,995
|
|
9.38
|
53,995
|
Total
loss-absorbing additional tier 1 capital
|
|
3.56
|
11,841
|
|
3.04
|
11,841
|
|
2.06
|
11,841
|
of which:
high-trigger loss-absorbing additional tier 1 capital
|
|
3.20
|
10,654
|
|
2.73
|
10,654
|
|
1.85
|
10,654
|
of which:
low-trigger loss-absorbing additional tier 1 capital
|
|
0.36
|
1,187
|
|
0.30
|
1,187
|
|
0.21
|
1,187
|
|
|
|
|
|
|
|
|
|
|
Risk-weighted
assets / leverage ratio denominator
|
|
|
|
|
|
|
|
|
|
Risk-weighted
assets
|
|
|
332,864
|
|
|
390,128
|
|
|
|
Leverage ratio denominator
|
|
|
|
|
|
|
|
|
575,461
|
|
|
|
|
|
|
|
|
|
|
Required gone
concern capital2
|
|
Higher of RWA- or LRD-based
|
|
|
|
|
|
|
Total gone concern
loss-absorbing capacity
|
|
|
40,106
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Eligible gone
concern capital
|
|
|
|
|
|
|
|
|
Total gone concern
loss-absorbing capacity
|
|
|
46,982
|
|
|
|
|
|
Gone concern
capital coverage ratio
|
|
117.15
|
|
|
|
|
|
|
|
1 Includes applicable add-ons of 1.44% for RWA and 0.50% for
LRD. 2 A maximum of 25% of the gone concern requirements can be met with
instruments that have a remaining maturity of between one and two years. Once
at least 75% of the minimum gone concern requirement has been met with
instruments that have a remaining maturity of greater than two years, all
instruments that have a remaining maturity of between one and two years
remain eligible to be included in the total gone concern capital.
|
UBS AG standalone
regulatory information 43
Swiss SRB going and gone concern
information
|
USD m, except
where indicated
|
|
31.12.22
|
|
30.9.22
|
31.12.21
|
|
|
|
|
|
|
Eligible going
concern capital
|
|
|
|
|
|
Total going concern
capital
|
|
65,836
|
|
67,149
|
66,658
|
Total tier 1
capital
|
|
65,836
|
|
67,149
|
66,658
|
Common equity tier
1 capital
|
|
53,995
|
|
53,480
|
52,818
|
Total
loss-absorbing additional tier 1 capital
|
|
11,841
|
|
13,669
|
13,840
|
of which:
high-trigger loss-absorbing additional tier 1 capital
|
|
10,654
|
|
12,481
|
11,414
|
of which:
low-trigger loss-absorbing additional tier 1 capital
|
|
1,187
|
|
1,188
|
2,426
|
|
|
|
|
|
|
Eligible gone
concern capital
|
|
|
|
|
|
Total gone concern
loss-absorbing capacity
|
|
46,982
|
|
45,375
|
44,250
|
Total tier 2
capital
|
|
2,949
|
|
2,949
|
3,129
|
of which:
low-trigger loss-absorbing tier 2 capital
|
|
2,421
|
|
2,426
|
2,594
|
of which:
non-Basel III-compliant tier 2 capital
|
|
528
|
|
523
|
535
|
TLAC-eligible
senior unsecured debt
|
|
44,033
|
|
42,426
|
41,120
|
|
|
|
|
|
|
Total
loss-absorbing capacity
|
|
|
|
|
|
Total
loss-absorbing capacity
|
|
112,818
|
|
112,524
|
110,908
|
|
|
|
|
|
|
Denominators for
going and gone concern ratios
|
|
|
|
|
|
Risk-weighted
assets phase-in
|
|
332,864
|
|
323,364
|
317,913
|
of which: investments
in Switzerland-domiciled subsidiaries1
|
|
39,589
|
|
37,427
|
38,935
|
of which:
investments in foreign-domiciled subsidiaries1
|
|
121,021
|
|
115,512
|
108,982
|
Risk-weighted
assets fully applied as of 1.1.28
|
|
390,128
|
|
377,973
|
382,934
|
of which:
investments in Switzerland-domiciled subsidiaries1
|
|
44,988
|
|
42,530
|
45,273
|
of which:
investments in foreign-domiciled subsidiaries1
|
|
172,887
|
|
165,018
|
167,664
|
Leverage ratio
denominator
|
|
575,461
|
|
553,215
|
593,868
|
|
|
|
|
|
|
Capital and loss-absorbing
capacity ratios (%)
|
|
|
|
|
|
Going concern
capital ratio, phase-in
|
|
19.8
|
|
20.8
|
21.0
|
of which: common
equity tier 1 capital ratio, phase-in
|
|
16.2
|
|
16.5
|
16.6
|
Going concern
capital ratio, fully applied as of 1.1.28
|
|
16.9
|
|
17.8
|
17.4
|
of which: common
equity tier 1 capital ratio, fully applied as of 1.1.28
|
|
13.8
|
|
14.1
|
13.8
|
|
|
|
|
|
|
Leverage ratios
(%)
|
|
|
|
|
|
Going concern
leverage ratio
|
|
11.4
|
|
12.1
|
11.2
|
of which: common
equity tier 1 leverage ratio
|
|
9.4
|
|
9.7
|
8.9
|
|
|
|
|
|
|
Capital coverage
ratio (%)
|
|
|
|
|
|
Gone concern
capital coverage ratio
|
|
117.1
|
|
117.8
|
112.0
|
1 Net exposures for direct and indirect investments including
holding of regulatory capital instruments in Switzerland-domiciled
subsidiaries and for direct and indirect investments including holding of
regulatory capital instruments in foreign-domiciled subsidiaries are
risk-weighted at 220% and 280%, respectively, for the current year. Risk
weights will gradually increase by 5 percentage points per year for Switzerland-domiciled
investments and 20 percentage points per year for foreign-domiciled
investments until the fully applied risk weights of 250% and 400%,
respectively, are applied.
|
Leverage ratio information
Swiss SRB leverage ratio denominator
|
|
|
|
|
USD bn
|
|
31.12.22
|
30.9.22
|
31.12.21
|
|
|
|
|
|
Leverage ratio denominator
|
|
|
|
|
Swiss GAAP total
assets
|
|
504.8
|
486.1
|
509.9
|
Difference between
Swiss GAAP and IFRS total assets
|
|
156.1
|
196.4
|
125.0
|
Less derivatives
and SFTs1
|
|
(254.7)
|
(310.8)
|
(216.4)
|
Less funding
provided to significant regulated subsidiaries eligible as gone concern
capital
|
|
(21.9)
|
(20.8)
|
(21.8)
|
On-balance sheet
exposures (excluding derivatives and SFTs)
|
|
384.3
|
350.9
|
396.7
|
Derivatives
|
|
88.3
|
101.7
|
89.7
|
Securities
financing transactions
|
|
80.7
|
79.4
|
85.4
|
Off-balance sheet
items
|
|
23.7
|
22.6
|
23.7
|
Items deducted
from Swiss SRB tier 1 capital
|
|
(1.7)
|
(1.4)
|
(1.6)
|
Total exposures
(leverage ratio denominator)
|
|
575.5
|
553.2
|
593.9
|
1 The exposures consist of derivative financial instruments,
cash collateral receivables on derivative instruments, receivables from SFTs,
and margin loans, as well as prime brokerage receivables and financial assets
at fair value not held for trading, both related to SFTs. These exposures are
presented separately under Derivatives and Securities financing transactions
in this table.
|
p
UBS AG standalone
regulatory information 44
Climate risk
Annual | Our
climate strategy and governance are determined and overseen at Group level.
Similarly, we identify and manage climate risks, including climate-related
financial risks, in our own operations, balance sheet, client assets and supply
chain on Group level.
In 2022, we made good progress on the execution of our
sustainability strategy, and we will continue to advance our own efforts
towards the 17 Sustainable Development Goals, recognizing that we, like our
clients, have much to learn as we move forward.
Climate-related metrics for the legal entity UBS AG are
presented along with respective metrics applicable to UBS Group in the UBS
Group AG Annual Report 2022.
› Refer to “Our focus on sustainability and climate” of the “How
we create value for our stakeholders” section and to “Sustainability and
climate risk” of the “Risk management and control” section of the UBS Group AG
Annual Report 2022 for more information
› Refer to “Our sustainability and impact strategy” in the
“Strategy” section of the Sustainability Report 2022, available
from 10 March 2023 under “Annual reporting” at ubs.com/investors, for more information
Non-financial report
UBS Group AG and UBS AG have issued a separate non-financial
group report in line with the Global Reporting Initiative (GRI). This report
provides disclosures on environmental, social and governance (ESG) matters for
UBS as a group. For UBS AG and its consolidated subsidiaries, this report also
provides the disclosures on non-financial information required by the German
law implementing EU Directive 2014/95 (CSR-Richtlinie-Umsetzungsgesetz /
CSR-RUG), in accordance with Art. 114 of the Securities Trading Act (Wertpapierhandelsgesetz
/ WpHG), and for UBS AG on a standalone basis, it provides disclosure
under Art. 8 of the EU Taxonomy Regulation. The report is available under
“Annual reporting” at ubs.com/investors.
› Refer to the Sustainability Report 2022 available at ubs.com/investors, for more information
UBS AG standalone
regulatory information 45
Cautionary Statement | This
report and the information contained herein are provided solely for information
purposes, and are not to be construed as solicitation of an offer to buy or
sell any securities or other financial instruments in Switzerland, the United
States or any other jurisdiction. No investment decision relating to securities
of or relating to UBS Group AG, UBS AG or their affiliates should be made on
the basis of this report. Refer to UBS’s most recent Annual Report on Form 20-F,
quarterly reports and other information furnished to or filed with the US Securities
and Exchange Commission on Form 6-K, available at ubs.com/investors, for
additional information.
Rounding | Numbers presented throughout this report may not
add up precisely to the totals provided in the tables and text. Percentages and
percent changes disclosed in text and tables are calculated on the basis of
unrounded figures. Absolute changes between reporting periods disclosed in the
text, which can be derived from numbers presented in related tables, are
calculated on a rounded basis.
Tables |
Within tables, blank fields generally indicate non-applicability or that
presentation of any content would not be meaningful, or that information is not
available as of the relevant date or for the relevant period. Zero values
generally indicate that the respective figure is zero on an actual or rounded
basis. Values that are zero on a rounded basis can be either negative or
positive on an actual basis.
UBS
Group AG
P.O. Box
CH-8098 Zurich
ubs.com
Zurich, 06 March
2023
Consent of
Independent Registered Public Accounting Firm
We consent to the
incorporation by reference in each of the following registration statements of
UBS Group AG, UBS AG and their affiliates:
(1) on Form F-3
(Registration Number 333-263376), and
each related prospectus currently outstanding under such registration statement,
(2)
on
Form S-8 (Registration Numbers 333-200634; 333-200635; 333-200641; 333-200665;
333-215254; 333-215255; 333-228653; and 333-230312; 333-249143), and each related prospectus currently
outstanding under any of the aforementioned registration statements,
(3)
the
base prospectus of Corporate Asset Backed Corporation (CABCO) dated 23 June
2004 (Registration Number 333-111572),
(4)
the
Form 8-K of CABCO dated 23 June 2004 (SEC File Number 001-13444), and
(5)
the
Prospectus Supplements relating to the CABCO Series 2004-101 Trust dated 10 May
2004 (Registration Number 033-91744) and 17 May 2004 (Registration Number
033-91744-05),
of our report
dated 03 March 2023, with respect to the standalone financial statements of UBS
AG for the year ended 31 December 2022 included in this Report of Foreign
Private Issuer (Form 6-K) dated 06 March 2023, filed
with the Securities and Exchange Commission.
/s/ Ernst & Young Ltd
This Form 6-K is hereby
incorporated by reference into (1) each of the registration statements of UBS
AG on Form F-3 (Registration Number 333-263376), and of UBS Group AG on Form
S-8 (Registration Numbers 333-200634; 333-200635; 333-200641; 333-200665;
333-215254; 333-215255; 333-228653; 333-230312; and 333-249143), and into each
prospectus outstanding under any of the foregoing registration statements, (2)
any outstanding offering circular or similar document issued or authorized by
UBS AG that incorporates by reference any Forms 6-K of UBS AG that are
incorporated into its registration statements filed with the SEC, and (3) the
base prospectus of Corporate Asset Backed Corporation (“CABCO”) dated June 23,
2004 (Registration Number 333-111572), the Form 8-K of CABCO filed and dated
June 23, 2004 (SEC File Number 001-13444), and the Prospectus Supplements
relating to the CABCO Series 2004-101 Trust dated May 10, 2004 and May 17, 2004
(Registration Number 033-91744 and 033-91744-05).
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrants have duly caused this report to be signed
on their behalf by the undersigned, thereunto duly authorized.
UBS Group AG
By: _/s/ Christopher Castello_______
Name: Christopher Castello
Title: Group Controller and
Chief Accounting Officer
By: _/s/ David Kelly _____________
Name: David Kelly
Title: Managing Director
UBS AG
By: _/s/ Christopher Castello_______
Name: Christopher Castello
Title: Controller and Chief
Accounting Officer
By: _/s/ David Kelly _____________
Name: David Kelly
Title: Managing Director
Date: March 6, 2023
UBS (NYSE:UBS)
Historical Stock Chart
From Mar 2024 to Apr 2024
UBS (NYSE:UBS)
Historical Stock Chart
From Apr 2023 to Apr 2024